Question,Complex_CoT,Response
"Patient is a 71 years old female, height 1.56m and weighs 51kg. Latest heart rate is 92 bpm. Latest systolic blood pressure is 113. Patient has past medical history of Parkinson disease, Type 2 Diabetes Mellitus, Stable Ischemic Heart Disease. Currently patient is admitted for Vertigo,  Gastroesophageal reflux disease. 
Patient is also taking the following medications: Oral Glipizide 15mg two times a day before meal, Oral Clopidogrel 75mg every morning, Oral Benserazide 25 mg/levodopa 100 mg twice a day. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 2.32 10^9/L
Haemoglobin = 11.3 g/dL
Platelet = 56.0 g/dL
Creatinine Clearance = 61.0 mL/min
eGFR = 55.0 mL/min/1.73 mÂ²
Sodium = 141 mmol/L
Potassium = 4.0 mmol/L
Magnesium = 0.8 mmol/L
Fasting Glucose = 7.1 mmol/L
HbA1C = 6.5 %
Hdl Hdl = 0.5 mmol/L
LDL = 2.0 mmol/L
TG = 2.0 mmol/L
Microbiology Report: null
Imaging Report: Chest X-ray: No significant lung consolidation, pleural effusion or pneumothorax. Cardiomediastinal contour unremarkable

The doctor ordered oral metoclopramide 10mg three times a day.

Drug Monography Information as below:
WARNING: TARDIVE DYSKINESIA Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped. Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia. See WARNINGS DOSAGE AND ADMINISTRATION Therapy with metoclopramide oral solution should not exceed 12 weeks in duration. For the Relief of Symptomatic Gastroesophageal Reflux Administer from 10 mg to 15 mg metoclopramide orally up to 4 times daily 30 minutes before each meal and at bedtime, depending upon symptoms being treated and clinical response (see CLINICAL PHARMACOLOGY and INDICATIONS AND USAGE ). If symptoms occur only intermittently or at specific times of the day, use of metoclopramide in single doses up to 20 mg prior to the provoking situation may be preferred rather than continuous treatment. Occasionally, patients (such as elderly patients) who are more sensitive to the therapeutic or adverse effects of metoclopramide will require only 5 mg per dose. Experience with esophageal erosions and ulcerations is limited, but healing has thus far been documented in one controlled trial using 4 times daily therapy at 15 mg/dose, and this regimen should be used when lesions are present, so long as it is tolerated (see ADVERSE REACTIONS ). Because of the poor correlation between symptoms and endoscopic appearance of the esophagus, therapy directed at esophageal lesions is best guided by endoscopic evaluation. Therapy longer than 12 weeks has not been evaluated and cannot be recommended. For the Relief of Symptoms Associated with Diabetic Gastroparesis (Diabetic Gastric Stasis) Administer 10 mg of metoclopramide 30 minutes before each meal and at bedtime for two to eight weeks, depending upon response and the likelihood of continued well-being upon drug discontinuation. The initial route of administration should be determined by the severity of the presenting symptoms. If only the earliest manifestations of diabetic gastric stasis are present, oral administration of metoclopramide may be initiated. However, if severe symptoms are present, therapy should begin with metoclopramide injection (consult labeling of the injection prior to initiating parenteral administration). Administration of metoclopramide injection up to 10 days maybe required before symptoms subside at which time oral administration may be instituted. Since diabetic gastric stasis is frequently recurrent, metoclopramide therapy should be reinstituted at the earliest manifestation. Use in Patients with Renal or Hepatic Impairment Since metoclopramide is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate. See OVERDOSAGE section for information regarding dialysis. Metoclopramide undergoes minimal hepatic metabolism, except for simple conjugation. Its safe use has been described in patients with advanced liver disease whose renal function was normal. WARNINGS Mental depression has occurred in patients with and without prior history of depression. Symptoms have ranged from mild to severe and have included suicidal ideation and suicide. Metoclopramide should be given to patients with a prior history of depression only if the expected benefits outweigh the potential risks. Extrapyramidal symptoms, manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at the higher doses. These symptoms may include involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus. Rarely, dystonic reactions may present as stridor and dyspnea, possibly due to laryngospasm. If these symptoms should occur, inject 50 mg diphenhydramine hydrochloride intramuscularly, and they usually will subside. Benztropine mesylate, 1 to 2 mg intramuscularly, may also be used to reverse these reactions. Parkinsonian-like symptoms have occurred, more commonly within the first 6 months after beginning treatment with metoclopramide, but occasionally after longer periods. These symptoms generally subside within 2 to 3 months following discontinuance of metoclopramide. Patients with preexisting Parkinsonâ€™s disease should be given metoclopramide cautiously, if at all, since such patients may experience exacerbation of parkinsonian symptoms when taking metoclopramide. Tardive Dyskinesia (see Boxed Warnings) Treatment with metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. The risk of developing tardive dyskinesia increases with duration of treatment and the total cumulative dose. An analysis of utilization patterns showed that about 20% of patients who used metoclopramide took it for longer than 12 weeks. Treatment with metoclopramide for longer than the recommended 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD. Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose. Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn. Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD. Neuroleptic Malignant Syndrome (NMS) There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias). The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever and primary central nervous system (CNS) pathology. The management of NMS should include 1) immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. Bromocriptine and dantrolene sodium have been used in treatment of NMS, but their effectiveness have not been established (see ADVERSE REACTIONS ).","Okay, so I'm trying to figure out if the doctor's order for metoclopramide is safe for this patient. Let me start by going through all the information provided.

The patient is a 71-year-old woman with Parkinson's disease, Type 2 Diabetes, and stable ischemic heart disease. She's currently admitted for vertigo and gastroesophageal reflux disease. Her medications include glipizide, clopidogrel, and levodopa/benserazide. She has no known allergies.

She's being treated for vertigo and GERD with metoclopramide 10mg three times a day. 

Looking at the drug monograph,  it mentioned that patients with preexisting Parkinson's disease should be given metoclopramide cautiously, if at all, since such patients may experience exacerbation of parkinsonian symptoms when taking metoclopramide. This patient has Parkinson's disease. This is a significant risk factor. This order is already appearing to be not safe.

Looking at her lab results: her eGFR is 55, which is just above the threshold for renal impairment (usually 60 or above is okay, so 55 might be a bit low but not necessarily problematic yet). Her sodium is 141, which is within normal range. Her potassium is 4.0, which is within normal range. Magnesium is 0.8, which seems normal.

Her fasting glucose is 7.1, and HbA1C is 6.5%, which are both within target range for diabetes management. Her cholesterol levels are normal as well.

The drug monography mentioned that treatment with metoclopramide can cause tardive dyskinesia. This risk increases with duration of treatment and total dose. The warning says to avoid using it for longer than 12 weeks unless absolutely necessary. Let me see if this is relevant to the patient. Here, the patient is being treated for vertigo and GERD. These diagnosis are usually acute in nature. Will the patient be on metoclopramide for 12 weeks? For an acute diagnosis, I don't think the patient will be on long term metoclopramide. I am assuming metoclopramide is newly initiated.  

Also, the patient's age is a factor. The elderly are more prone to developing tardive dyskinesia, and the risk increases with age. Her age is 71, which is quite advanced, so this adds another layer of concern.

The patient's current issue of vertigo and GERD makes metoclopramide a reasonable treatment, but the risk of worsening Parkinsonism symptoms and tardive dyskinesia is significant, especially given her age and history of Parkinson's disease. 

In conclusion, the risk of metoclopramide significantly outweighs the benefit due to the patient's medical history of Parkinson's disease and age. Use should be avoided in patients with Parkinson disease and other patients being treated with antiparkinsonian drugs.",This medication order is not safe because symptoms of Parkinson disease may be exacerbated with metoclopramide use. The doctor should discontinue the medication.
"Patient is a 31 years old male, height 1.68m and weighs 86kg. Latest heart rate is 87 bpm. Latest systolic blood pressure is 119. Patient has past medical history of Hypertension. Currently patient is admitted for Rhabdomylosis, Transaminitis. 
Patient is also taking the following medications: Oral Atenolol 50mg two times a day. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 9.56 10^9/L
Haemoglobin = 14.9 g/dL
Platelet = 318.0 g/dL
Urea = 2.8 mmol/L
eGFR = 111.0 mL/min/1.73 mÂ²
Sodium = 138 mmol/L
Potassium = 4.0 mmol/L
Bicarbonate = 28.0 mmol/L
AST = 73.0 U/L
ALT = 160.0 U/L
Albumin = 46.0 g/L
Creatinine Kinase = 52275.0 U/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral metoclopramide 10mg three times a day.

Drug Monography Information as below:
WARNING: TARDIVE DYSKINESIA Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped. Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia. See WARNINGS DOSAGE AND ADMINISTRATION Therapy with metoclopramide oral solution should not exceed 12 weeks in duration. For the Relief of Symptomatic Gastroesophageal Reflux Administer from 10 mg to 15 mg metoclopramide orally up to 4 times daily 30 minutes before each meal and at bedtime, depending upon symptoms being treated and clinical response (see CLINICAL PHARMACOLOGY and INDICATIONS AND USAGE ). If symptoms occur only intermittently or at specific times of the day, use of metoclopramide in single doses up to 20 mg prior to the provoking situation may be preferred rather than continuous treatment. Occasionally, patients (such as elderly patients) who are more sensitive to the therapeutic or adverse effects of metoclopramide will require only 5 mg per dose. Experience with esophageal erosions and ulcerations is limited, but healing has thus far been documented in one controlled trial using 4 times daily therapy at 15 mg/dose, and this regimen should be used when lesions are present, so long as it is tolerated (see ADVERSE REACTIONS ). Because of the poor correlation between symptoms and endoscopic appearance of the esophagus, therapy directed at esophageal lesions is best guided by endoscopic evaluation. Therapy longer than 12 weeks has not been evaluated and cannot be recommended. For the Relief of Symptoms Associated with Diabetic Gastroparesis (Diabetic Gastric Stasis) Administer 10 mg of metoclopramide 30 minutes before each meal and at bedtime for two to eight weeks, depending upon response and the likelihood of continued well-being upon drug discontinuation. The initial route of administration should be determined by the severity of the presenting symptoms. If only the earliest manifestations of diabetic gastric stasis are present, oral administration of metoclopramide may be initiated. However, if severe symptoms are present, therapy should begin with metoclopramide injection (consult labeling of the injection prior to initiating parenteral administration). Administration of metoclopramide injection up to 10 days maybe required before symptoms subside at which time oral administration may be instituted. Since diabetic gastric stasis is frequently recurrent, metoclopramide therapy should be reinstituted at the earliest manifestation. Use in Patients with Renal or Hepatic Impairment Since metoclopramide is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate. See OVERDOSAGE section for information regarding dialysis. Metoclopramide undergoes minimal hepatic metabolism, except for simple conjugation. Its safe use has been described in patients with advanced liver disease whose renal function was normal. WARNINGS Mental depression has occurred in patients with and without prior history of depression. Symptoms have ranged from mild to severe and have included suicidal ideation and suicide. Metoclopramide should be given to patients with a prior history of depression only if the expected benefits outweigh the potential risks. Extrapyramidal symptoms, manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at the higher doses. These symptoms may include involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus. Rarely, dystonic reactions may present as stridor and dyspnea, possibly due to laryngospasm. If these symptoms should occur, inject 50 mg diphenhydramine hydrochloride intramuscularly, and they usually will subside. Benztropine mesylate, 1 to 2 mg intramuscularly, may also be used to reverse these reactions. Parkinsonian-like symptoms have occurred, more commonly within the first 6 months after beginning treatment with metoclopramide, but occasionally after longer periods. These symptoms generally subside within 2 to 3 months following discontinuance of metoclopramide. Patients with preexisting Parkinsonâ€™s disease should be given metoclopramide cautiously, if at all, since such patients may experience exacerbation of parkinsonian symptoms when taking metoclopramide. Tardive Dyskinesia (see Boxed Warnings) Treatment with metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. The risk of developing tardive dyskinesia increases with duration of treatment and the total cumulative dose. An analysis of utilization patterns showed that about 20% of patients who used metoclopramide took it for longer than 12 weeks. Treatment with metoclopramide for longer than the recommended 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD. Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose. Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn. Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD. Neuroleptic Malignant Syndrome (NMS) There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias). The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever and primary central nervous system (CNS) pathology. The management of NMS should include 1) immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. Bromocriptine and dantrolene sodium have been used in treatment of NMS, but their effectiveness have not been established (see ADVERSE REACTIONS ).","Okay, so I need to figure out if the medication order for metoclopramide is safe for this patient. Let me start by looking at the patient's details. He's a 31-year-old male with a history of hypertension and currently admitted for rhabdomyolysis and transaminitis. His current medications include oral atenolol for hypertension. He doesn't have any known allergies, which is good.

Looking at his lab results, his urea is slightly elevated at 2.8 mmol/L, and his eGFR is 111 mL/min/1.73 mÂ², which is within normal range. His sodium is 138 mmol/L, which is a bit on the higher side but not significantly elevated. Potassium is 4.0 mmol/L, which is within normal. Bicarbonate is 28.0 mmol/L, also normal. His AST is 73 U/L and ALT is 160 U/L, which suggests some liver stress but not severe. His albumin is 46 g/L, which is normal. All good so far. 

He's been prescribed oral metoclopramide 10mg three times a day. Now, looking at the drug monography, metoclopramide has some warnings. The first  concern is tardive dyskinesia, which is a serious movement disorder. The risk increases with the duration of treatment and the total cumulative dose, especially if treated for longer than 12 weeks. Let's see if this is relevant to the patient. This patient is admitted in the hospital for rhabdomyolysis. Rhabdomyolisis is usually acute in nature, so I don't think the patient will be on metoclopramide for a long duration. This warning seems irrelevant to our patient, and the order seems okay for now.

Furthermore, from the drug monography, elderly patients are more sensitive to the therapeutic or adverse effects of metoclopramide. This patient is so young at only 31 years old. All good so far.

Also dosage recommended in monography goes from 10 mg to 15 mg metoclopramide orally up to 4 times daily. The current ordered dose of 10mg three times daily is within the range recommended.

Looking at the lab results again, there's no indication of infection or other complications that would require metoclopramide. But nausea and vomiting could potentially be symptoms of rhabdomyolysis, so patient might be taking metoclopramide for symptom relief.

In the drug monography, it is mentioned that metoclopramide is excreted through the kidneys, so in patients with renal impairment, the dosage should be adjusted. The patient's eGFR is 111, which is normal, so that is not an issue here.

Considering all this, the the benefits of taking metoclopramide seems to outweigh the risk. Therefore, the medication order is safe for the patient. ",This order is safe because it aligns with the general dose information in the drug monograph. The dose of 10mg three times a day is appropriate and the patient has no contraindication to metoclopramide. 
"Patient is a 70 years old male, height 1.62m and weighs 81kg. Latest heart rate is 83 bpm. Latest systolic blood pressure is 109. Patient has past medical history of Child-Turcotte-Pugh Class C, Decompensated Cirrhosis, Ischemic Heart Disease, Acute Coronary Syndrome, Hyperlipidemia, Chronic Liver Disease. Currently patient is admitted for Fall. 
Patient is also taking the following medications: Oral Bisoprolol 5mg every morning, Oral Aspirin 100mg every morning. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 10.1 10^9/L
Haemoglobin = 11.1 g/dL
Platelet = 125.0 g/dL
Urea = 16.0 mmol/L
Creatinine Clearance = 35.0 mL/min
Sodium = 132 mmol/L
Potassium = 4.3 mmol/L
Magnesium = 0.94 mmol/L
Calcium = 1.99 mmol/L
AST = 420.0 U/L
ALT = 90.0 U/L
Albumin = 20.0 g/L
Microbiology Report: null
Imaging Report: CT Thorax Abdomen and Pelvis:
Extensive right hepatic lobe changes very suspicious for HCC. This is in the area of the possible previous early hepatoma. The exact extent is difficult to assess with background cirrhotic changes. Collateral vessels and ascites. Possible left lung metastases and borderline mediastinal adenopathy.

The doctor ordered oral ibuprofen 200mg three times a day.

Drug Monography Information as below:
Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include: rash facial swelling asthma (wheezing) hives skin reddening shock blisters If an allergic reaction occurs, stop use and seek medical help right away. Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you: take more or for a longer time than directed take a blood thinning (anticoagulant) or steroid drug have had stomach ulcers or bleeding problems have 3 or more alcoholic drinks every day while using this product are age 60 or older take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others] Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed. Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery Ask a doctor before use if stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke you are taking a diuretic you have problems or serious side effects from taking pain relievers or fever reducers Ask a doctor or pharmacist before use if you are under a doctor's care for any serious condition taking aspirin for heart attack or stroke, because ibuprofen may decrease this benefit of aspirin taking any other drug When using this product take with food or milk if stomach upset occurs Stop use and ask a doctor if you experience any of the following signs of stomach bleeding: feel faint have bloody or black stools vomit blood have stomach pain that does not get better you have symptoms of heart problems or stroke: chest pain slurred speech leg swelling trouble breathing weakness in one part or side of body pain gets worse or lasts more than 10 days fever gets worse or lasts more than 3 days redness or swelling is present in the painful area any new symptoms appear If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use ibuprofen at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.","Okay, so I'm trying to figure out whether the medication order for ibuprofen is safe for this patient. Let me go through the information step by step.

First, the patient is a 70-year-old male with several medical conditions: Child-Turcotte-Pugh Class C, which means his liver is severely affected. He also has decompensated cirrhosis, ischemic heart disease, acute coronary syndrome, hyperlipidemia, and chronic liver disease. He's currently in the hospital for a fall.

He's taking bisoprolol and aspirin, which are both blood pressure and antiplatelet medications, respectively. His allergies are noted as null, so no known allergies.

Looking at his lab results: his white blood cell count is slightly elevated, but his platelet count is normal. His liver enzymes show AST is high (420 U/L) but ALT is only 90 U/L. His creatinine clearance is 35 mL/min, which is slightly reduced but not too bad. His electrolytes are within normal range except for sodium, which is a bit high at 132 mmol/L.

His imaging report shows extensive right hepatic lobe changes suspicious for HCC. That's concerning because HCC can be associated with liver dysfunction and potential complications. The collateral vessels and ascites might indicate fluid retention, which can be a problem, especially with medications that affect the kidneys or liver.

Now, the doctor ordered ibuprofen 200mg three times a day. I need to check the drug monography to see if there are any contraindications or warnings that apply to this patient.

Let us look through the alerts provided and see if they are relevant to our patient. 
- Allergy alert: Ibuprofen can cause severe allergic reactions, especially in those allergic to aspirin. This patient has no known drug allergy so that is not relevant. 
- Stomach bleeding warning: Higher risk if taking more than directed, blood thinners, steroids, history of ulcers or bleeding, heavy alcohol use, age over 60, or other NSAIDs. Other than being above 60 years old (since patient is 70 years old), patient do not have any of the other risk factors so this is not relevant too. 
- Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. Ibuprofen is a NSAID. Wait a minute, this patient has history of ischemic heart disease and acute coronary syndrome. Monography states that NSAIDs can increase the risk of heart attack, stroke, and heart failure, especially in older patients or those with pre-existing heart conditions. The patient is 70, which makes this risk higher. This is a significant risk factor for our patient. The medication order is unsafe for this patient. Okay let's see more factors, but bearing in mind that we have a significant risk factor of ischemic heart disease history.
- Stomach issues: High blood pressure, liver cirrhosis, kidney disease, etc. Given the patient's history of chronic liver disease and cirrhosis, he's at higher risk for complications from ibuprofen. The stomach bleeding and kidney issues are concerning because his creatinine clearance is slightly reduced.

The patient's history of acute coronary syndrome and ischemic heart disease raises the concern of cardiovascular complications. Ibuprofen, being an NSAID, can increase the risk of heart attack and stroke, especially if used improperly. 
The patient's age is a factor as well; he's over 60, which is a higher risk category for NSAID-related issues. In terms of the liver, the AST is significantly elevated, which could be a sign of worsening liver function. Ibuprofen can cause further strain on the liver, especially since he's already dealing with HCC.

The medication order for ibuprofen is not safe for this patient. The patient's history of ischemic heart disease, acute coronary syndrome, chronic liver disease, including decompensated cirrhosis and hepatocellular carcinoma, along with his age and other comorbidities, places him at significant risk for complications from ibuprofen. The potential for cardiovascular events, gastrointestinal bleeding, kidney issues, compounded by his existing conditions, outweighs the benefits of using ibuprofen. Therefore, the order is considered unsafe.","The medication order is not safe due to the presence of multiple risk factors such as old age, history of ischemic heart disease and decompensated cirrhosis. These increases the risk of serious fatal cardiovascular (CV) events and stomach issues. The medication order should be discontinued."
"Patient is a 31 years old female, height 1.68m and weighs 49kg. Latest heart rate is 87 bpm. Latest systolic blood pressure is 119. Patient has past medical history of null. Currently patient is admitted for Trigger Finger. 
Patient is also taking the following medications: null. 
Patient has known allergy to: tramadol.

Some recent lab results and reports are shown below:
White Blood Cell = 9.2 10^9/L
Haemoglobin = 12.5 g/dL
Platelet = 56.0 g/dL
Creatinine Clearance = 80.0 mL/min
eGFR = 64.0 mL/min/1.73 mÂ²
Sodium = 140 mmol/L
Potassium = 4.1 mmol/L
Magnesium = 0.9 mmol/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral ibuprofen 1 tablet (200mg) three times a day.

Drug Monography Information as below:
Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include: rash facial swelling asthma (wheezing) hives skin reddening shock blisters If an allergic reaction occurs, stop use and seek medical help right away. Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you: take more or for a longer time than directed take a blood thinning (anticoagulant) or steroid drug have had stomach ulcers or bleeding problems have 3 or more alcoholic drinks every day while using this product are age 60 or older take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others] Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed. Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery Ask a doctor before use if stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke you are taking a diuretic you have problems or serious side effects from taking pain relievers or fever reducers Ask a doctor or pharmacist before use if you are under a doctor's care for any serious condition taking aspirin for heart attack or stroke, because ibuprofen may decrease this benefit of aspirin taking any other drug When using this product take with food or milk if stomach upset occurs Stop use and ask a doctor if you experience any of the following signs of stomach bleeding: feel faint have bloody or black stools vomit blood have stomach pain that does not get better you have symptoms of heart problems or stroke: chest pain slurred speech leg swelling trouble breathing weakness in one part or side of body pain gets worse or lasts more than 10 days fever gets worse or lasts more than 3 days redness or swelling is present in the painful area any new symptoms appear If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use ibuprofen at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.","Alright, let's try to figure this out. So, the question is whether the medication order for ibuprofen is safe for the patient. The patient is a 31-year-old female with some specific details. Let me break it down step by step.

First, the patient's medical history is listed as ""null,"" which I think means she has no past medical history. She's being admitted for trigger finger. Trigger finger may cause pain and stiffness of the fingers. Seems like our patient might be requiring some pain relief at the moment. Ibuprofen, which is an anti-inflammatory, can help with pain relief. Let's see if it is safe for her.

She's taking no medications currently, but she has a known allergy to tramadol. But tramadol is an opioid, and ibuprofen is a non-steroidal anti-inflammatory drug (NSAID). They're different classes, so I think ibuprofen should be okay for her.

Her lab results appear unremarkable. The doctor ordered oral ibuprofen 1 tablet (200mg) three times a day. Let me check the drug monography for any contraindications or warnings that might make this unsafe.

There is a stomach bleeding warning. Is this relevant to our patient? Let's see. The patient has no history of stomach issues, so I don't think there is a a contraindication. She's 31, not age 60 or older, so the higher risk isn't as much. She's not taking blood thinners or steroids, so that's not an issue.

She doesn't have a history of any heart attack or stroke, so no contraindications there. And she's young. She's not taking other NSAIDs, as per the medication list. So, that's not a problem. The doctor should ask about a history of stomach problems, high blood pressure, heart disease, etc. She doesn't have a history of those, so that's not an issue. Since she's not pregnant, that's not a concern.

In terms of the dosage, the doctor is directing 1 tablet three times a day, which is 600mg daily. The maximum is 6 tablets in 24 hours,  that is fine. Considering all this, the ibuprofen order seems safe. The only minor concern is the potential for stomach bleeding or NSAID-related side effects, but given her age and lack of other risk factors, I think the patient will benefit from the symptomatic relief more for now. I think I've covered all the points. The medication order is safe for the patient.
",This ibuprofen order is safe because the dose of 1 tablet (200mg) three times a day is an appropriate dose and the patient has no significant risk factors that are contraindications to ibuprofen.
"Patient is a 43 years old male, height 1.65m and weighs 85kg. Latest heart rate is 78 bpm. Latest systolic blood pressure is 125. Patient has past medical history of Diabetes Melitus Type 2, Hyperlipidemia. Currently patient is admitted for Acute Kidney Injury secondary to Gastroenteritis, Community Acquired Pneumonia. 
Patient is also taking the following medications: null. 
Patient has known allergy to: glipizide.

Some recent lab results and reports are shown below:
White Blood Cell = 9.5 10^9/L
Haemoglobin = 14.7 g/dL
Platelet = 403.0 g/dL
High Sensitive C-Reactive Protein = 21.6 mg/L
Urea = 4.8 mmol/L
Creatinine Clearance = 16.0 mL/min
eGFR = 25.0 mL/min/1.73 mÂ²
Sodium = 137 mmol/L
Potassium = 4.7 mmol/L
AST = 32.0 U/L
ALT = 62.0 U/L
Albumin = 35.0 g/L
Fasting Glucose = 7.8 mmol/L
HbA1C = 7.9 %
Microbiology Report: null
Imaging Report: Chest X-ray: Left lower zone airspace changes and possible small left pleural effusion. Mild right infrahilar airspace changes Biapical pleural thickening/scarring and fibronodular scarring in the right upper zone. The heart size is not accurately assessed on this projection.  Degenerative changes are noted in the imaged spine.

The doctor ordered oral metformin 1g twice a day (after meals).

Drug Monography Information as below:
WARNING: LACTIC ACIDOSIS WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. ( 5.1 ) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin- associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. ( 5.1 ) If lactic acidosis is suspected, discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. ( 5.1 ) Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin- associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [ see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [ see Dosage and Administration (2.2) , Contraindications (4) , Warnings and Precautions (5.1) ]. If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [ see Warnings and Precautions (5.1) ]. 2 DOSAGE AND ADMINISTRATION Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew ( 2.1 ) Starting dose: 500 mg orally once daily with the evening meal ( 2.1 ) Increase the dose in increments of 500 mg weekly, up to a maximum of 2,000 mg once daily with the evening meal ( 2.1 ) Patients receiving metformin hydrochloride (HCl) tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 ( 2.2 ) Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 ( 2.2 ) Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 ( 2.2 ) Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 ( 2.2 ) Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures ( 2.3 ) 2.1 Adult Dosage and Administration Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew. The recommended starting dose of metformin hydrochloride extended-release tablets is 500 mg orally once daily with the evening meal. Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal. If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily. Patients receiving metformin hydrochloride (HCl) may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily. 2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter. Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m 2 . Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m 2 is not recommended. In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/min/1.73 m 2 , assess the benefit risk of continuing therapy. Discontinue metformin hydrochloride extended-release tablets if the patient's eGFR later falls below 30 mL/minute/1.73 m 2 [ see Contraindications (4) and Warnings and Precautions (5.1) ]. 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable. 8.1 Pregnancy Risk Summary Limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see Data ] . There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [ see Clinical Considerations ]. No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2- and 5- times, respectively, a 2550 mg clinical dose, based on body surface area [see Data]. The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes mellitus with an HbA 1C >7 and has been reported to be as high as 20 to 25% in women with a HbA 1C >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Human Data Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups. Animal Data Metformin HCl did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 5 times a 2550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.","Okay, so I need to determine whether the medication order for metformin is safe for this patient. Let me start by going through all the information provided.

The patient is a 43-year-old male with a history of diabetes and hyperlipidemia. He's currently admitted for acute kidney injury (AKI) secondary to gastroenteritis and community-acquired pneumonia. His current medications are listed as null, which is a bit unusual, but maybe he wasn't taking anything before. He has a known allergy to glipizide, which is another diabetes medication, so that's something to consider.

Looking at his lab results: his eGFR is 25 mL/min/1.73m2, which is below the stated threshold of 30 that would be contraindicated for metformin. This fails the order immediately. This order is definitely not safe for the patient. But let's look through the case more.

The doctor ordered oral metformin 1g twice a day after meals. Metformin is commonly used for type 2 diabetes, but it has some risks, especially related to lactic acidosis, which can be fatal. The drug monography provided has a lot of warnings about metformin-associated lactic acidosis, listing several risk factors.

Now, the key points to consider are:

1.The patient's eGFR is 25. The prescribing information says metformin is contraindicated below 30. Do not use in patients with eGFR below 30 mL/minute/1.73 m 2. This seems to be an absolute contraindication, and should be the most important factor to consider.

2.The patient has acute kidney injury, which is a risk factor for lactic acidosis.

3. The patient is in the hospital for an infection. Are there other risk factors for lactic acidosis? The monography lists factors like hypoxic states, which the patient might have due to his pneumonia. The risk of lactic acidosis increases with factors like acute congestive heart failure, which isn't mentioned, but the pneumonia might affect oxygen levels.

The patient's current glucose levels: Fasting glucose is 7.8 mmol/L, which is slightly elevated but not diabetic. HbA1C is 7.9%, which is just below the diagnostic threshold for diabetes. So, maybe the metformin is being started before the diabetes is fully established, but still, the risks of metformin apply regardless.

Putting it all together, the patient has an eGFR of 25, which is below 30. Use of Metformin is contraindicated. Moreover, the patient's current condition (AKI and pneumonia) might increase the risk of lactic acidosis. Given all this, the medication order for metformin in this patient isn't safe and the order should be discontinued.","This order is not safe because  the patient's eGFR is 25 ml/min/m 2. From the drug monography, use of Metformin is contraindicated in patients with eGFR below 30 mL/minute/1.73 m 2.  Furthermore, this patient is having acute kidney injury which increases risk of lactic acidosis. Metformin should be held off until renal function has improved."
"Patient is a 55 years old male, height 1.75m and weighs 78kg. Latest heart rate is 85 bpm. Latest systolic blood pressure is 130. Patient has past medical history of Type 2 Diabetes Mellitus. Currently patient is admitted for Total Hip Replacement. 
Patient is also taking the following medications: Oral Linagliptin 5mg every morning. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 5.3 10^9/L
Haemoglobin = 10.9 g/dL
Platelet = 56.0 g/dL
Creatinine Clearance = 65.0 mL/min
eGFR = 59.0 mL/min/1.73 mÂ²
Sodium = 142 mmol/L
Potassium = 4.0 mmol/L
Magnesium = 0.96 mmol/L
Fasting Glucose = 8.6 mmol/L
HbA1C = 7.5 %
Microbiology Report: null
Imaging Report: null

The doctor ordered oral metformin 500mg two times a day (after meals).

Drug Monography Information as below:
WARNING: LACTIC ACIDOSIS WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. ( 5.1 ) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin- associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. ( 5.1 ) If lactic acidosis is suspected, discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. ( 5.1 ) Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin- associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin- associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [ see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [ see Dosage and Administration (2.2) , Contraindications (4) , Warnings and Precautions (5.1) ]. If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [ see Warnings and Precautions (5.1) ]. 2 DOSAGE AND ADMINISTRATION Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew ( 2.1 ) Starting dose: 500 mg orally once daily with the evening meal ( 2.1 ) Increase the dose in increments of 500 mg weekly, up to a maximum of 2,000 mg once daily with the evening meal ( 2.1 ) Patients receiving metformin hydrochloride (HCl) tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 ( 2.2 ) Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 ( 2.2 ) Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 ( 2.2 ) Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 ( 2.2 ) Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures ( 2.3 ) 2.1 Adult Dosage and Administration Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew. The recommended starting dose of metformin hydrochloride extended-release tablets is 500 mg orally once daily with the evening meal. Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal. If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily. Patients receiving metformin hydrochloride (HCl) may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily. 2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter. Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m 2 . Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m 2 is not recommended. In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/min/1.73 m 2 , assess the benefit risk of continuing therapy. Discontinue metformin hydrochloride extended-release tablets if the patient's eGFR later falls below 30 mL/minute/1.73 m 2 [ see Contraindications (4) and Warnings and Precautions (5.1) ]. 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable. 8.1 Pregnancy Risk Summary Limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see Data ] . There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [ see Clinical Considerations ]. No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2- and 5- times, respectively, a 2550 mg clinical dose, based on body surface area [see Data]. The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes mellitus with an HbA 1C >7 and has been reported to be as high as 20 to 25% in women with a HbA 1C >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Human Data Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups. Animal Data Metformin HCl did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 5 times a 2550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.","Okay, so I'm trying to figure out whether the doctor's order of oral metformin 500mg twice a day is safe for this patient. Let's go through the information step by step.

First, the patient is a 55-year-old male with a height of 1.75 meters and a weight of 78 kg. His current vital signs are a heart rate of 85 bpm and a systolic blood pressure of 130 mmHg. He has a history of Type 2 Diabetes Mellitus and is currently admitted for a Total Hip Replacement. He's already taking oral Linagliptin 5mg daily, which is an incretin inhibitor used for diabetes. He has no known allergies.

Looking at the lab results: his white blood cell count is 5.3 x10^9/L, which is within normal range. His hemoglobin is 10.9 g/dL, which is also normal. Platelets are 56.0 g/dL, which is slightly low but not critically so. His creatinine clearance is 65 mL/min, and his eGFR is 59 mL/min/1.73 m2. Both of these are above the contraindication threshold of 30, so his kidneys are functioning adequately for metformin use.

Sodium is 142 mmol/L, which is within normal range, and potassium is 4.0 mmol/L, which is slightly high but not significantly so. Magnesium is 0.96 mmol/L, which is below the normal range of 1.1-1.6 mmol/L. Low magnesium can sometimes be a risk factor for arrhythmias, but it's not directly related to metformin use. Fasting glucose is 8.6 mmol/L, and HbA1C is 7.5%, both of which are controlled, so his diabetes is well managed.

The doctor is starting metformin, which is a common medication for Type 2 Diabetes. The drug monography warns about the risk of lactic acidosis, especially in high-risk patients. The risk factors include renal impairment, which the patient has a mild form of (eGFR 59), age over 65 (he is 55, but still in the higher end), concomitant use of other medications, and other factors like hypoxia or excessive alcohol.

He is already taking Linagliptin, which is an incretin inhibitor. There's no known interaction between metformin and Linagliptin stated in the drug monography.

The patient's surgery is a Total Hip Replacement, which is a major procedure. The drug monography warns that metformin should be discontinued before and during iodinated contrast imaging and procedures, but in this case, the patient is already on metformin, and the procedure is a hip replacement which is an orthopedic surgery. I should consider whether the anesthesia or surgery team will use contrast, but the information provided doesn't mention that. For orthopedic surgery, I am guessing it does not use iodinated contrast.

His eGFR is 59, which is above the 30 threshold, so the kidneys are okay. The warning mentions that if eGFR falls below 45, the patient should be reassessed. His current eGFR is 59, which is acceptable, so the kidney risk factors are not relevant for this patient.

The patient is admitted for surgery, so he'll be in a hospital setting where monitoring is more thorough. The surgery team can closely watch for any signs of lactic acidosis, such as malaise, myalgias, respiratory distress, or abdominal pain.

In summary, the patient's eGFR is acceptable, his diabetes is well-controlled, and the immediate situation of total hip replacement seems manageable. The metformin is a standard treatment for Type 2 Diabetes, and the surgery team can monitor for any signs of complications. This order is safe for the patient.",The medication order for oral metformin 500mg twice a day is considered safe for the patient under the given circumstances.The patient's current health status and lab results do not immediately indicate a high risk of lactic acidosis or other complications from metformin.
"Patient is a 55 years old male, height 1.75m and weighs 78kg. Latest heart rate is 85 bpm. Latest systolic blood pressure is 130. Patient has past medical history of Kidney Transplant, Hyperlipidemia, Hypertension. Currently patient is admitted for Mild Acute Rejection Episode. 
Patient is also taking the following medications: Oral Prednisolone 5mg every morning, Oral Cyclosporine 325mg twice a day. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 9.2 10^9/L
Haemoglobin = 12.5 g/dL
Platelet = 210.0 g/dL
High Sensitive C-Reactive Protein = 10.0 mg/L
Urea = 6.5 mmol/L
Creatinine Clearance = 65.0 mL/min
eGFR = 58.0 mL/min/1.73 mÂ²
Sodium = 138 mmol/L
Potassium = 4.5 mmol/L
Magnesium = 0.8 mmol/L
Calcium = 1.1 mmol/L
Bicarbonate = 22.0 mmol/L
AST = 35.0 U/L
ALT = 40.0 U/L
Albumin = 38.0 g/L
Fasting Glucose = 7.5 mmol/L
HbA1C = 8.2 %
Hdl Hdl = 1.0 mmol/L
LDL = 3.2 mmol/L
TG = 1.5 mmol/L
Microbiology Report: null
Imaging Report: Renal Ultrasound: No hydronephrosis, stable allograft

The doctor ordered oral rosuvastatin 20mg every night.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION Rosuvastatin tablets can be taken with or without food, at any time of day. (2.1) Dose range: 5 to 40 mg once daily. Use 40 mg dose only for patients not reaching LDLâ€‘C goal with 20 mg. (2.1) Adult HoFH: Starting dose 20 mg/day (2.1) 2.1 General Dosing Information The dose range for rosuvastatin tablet in adults is 5 to 40 mg orally once daily. The usual starting dose is 10 to 20 mg once daily. The usual starting dose in adult patients with homozygous familial hypercholesterolemia is 20 mg once daily. The maximum rosuvastatin tablet dose of 40 mg should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose [ see Warnings and Precautions (5.1) ]. Rosuvastatin tablets can be administered as a single dose at any time of day, with or without food. The tablet should be swallowed whole. When initiating rosuvastatin therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate rosuvastatin tablets starting dose should first be utilized, and only then titrated according to the patientâ€™s response and individualized goal of therapy. After initiation or upon titration of rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. Pediatric use information for patients 7 to 17 years of age is approved for AstraZenecaâ€™s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZenecaâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 2.3 Dosing in Asian Patients In Asian patients, consider initiation of rosuvastatin therapy with 5 mg once daily due to increased rosuvastatin plasma concentrations. The increased systemic exposure should be taken into consideration when treating Asian patients not adequately controlled at doses up to 20 mg/day [ see Use in Specific Populations (8.8) and Clinical Pharmacology (12.3) ]. 2.4 Use with Concomitant Therapy Patients taking cyclosporine and darolutamide The dose of rosuvastatin tablets should not exceed 5 mg once daily [ see Warnings and Precautions (5.1) , Drug Interactions (7.1) , Drug Interactions (7.4) and Clinical Pharmacology (12.3) ]. Patients taking gemfibrozil Avoid concomitant use of rosuvastatin with gemfibrozil. If concomitant use cannot be avoided, initiate rosuvastatin tablets at 5 mg once daily. The dose of rosuvastatin tablets should not exceed 10 mg once daily [ see Warnings and Precautions (5.1), Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. Patients taking regorafenib Concomitant use of rosuvastatin tablets and regorafenib, the dose of rosuvastatin tablets should not exceed 10 mg once daily [ see Warnings and Precautions (5.1), Drug Interactions (7.5) and Clinical Pharmacology (12.3) ]. Patients taking atazanavir and ritonavir, lopinavir and ritonavir, simeprevir or combination of dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir Initiate rosuvastatin therapy with 5 mg once daily. The dose of rosuvastatin tablets should not exceed 10 mg once daily [ see Warnings and Precautions (5.1) , Drug Interactions (7.3), and Clinical Pharmacology (12.3) ]. 2.5 Dosing in Patients with Severe Renal Impairment For patients with severe renal impairment (CL cr <30 mL/min/1.73 m 2 ) not on hemodialysis, dosing of rosuvastatin tablets should be started at 5 mg once daily and not exceed 10 mg once daily [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 8.1 Pregnancy Risk Summary Rosuvastatin is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit to therapy with rosuvastatin during pregnancy. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, rosuvastatin may cause fetal harm when administered to pregnant women. Rosuvastatin should be discontinued as soon as pregnancy is recognized [see Contraindications (4) ] . Limited published data on the use of rosuvastatin are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage. In animal reproduction studies, there were no adverse developmental effects with oral administration of rosuvastatin during organogenesis at systemic exposures equivalent to a maximum recommended human dose (MRHD) of 40 mg/day in rats or rabbits (based on AUC and body surface area, respectively). In rats and rabbits, decreased pup/fetal survival occurred at 12 times and equivalent, respectively, to the MRHD of 40 mg/day [see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Limited published data on rosuvastatin have not shown an increased risk of major congenital malformations or miscarriage. Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. The number of cases is adequate to exclude a â‰¥3 to 4-fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Animal Data Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. A higher fetal tissue distribution (25% maternal plasma concentration) was observed in rabbits after a single oral gavage dose of 1 mg/kg on gestation day 18. Rosuvastatin administration did not indicate a teratogenic effect in rats at â‰¤25 mg/kg/day or in rabbits â‰¤3 mg/kg/day (doses equivalent to the MRHD of 40 mg/day based on AUC and body surface area, respectively). In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC). In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area). In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).","Okay, I need to determine if the medication order for rosuvastatin is safe for this patient. Let me start by reviewing the patient's information and the drug monography.

The patient is a 55-year-old male with a kidney transplant, hyperlipidemia, and hypertension. He's currently admitted for a mild acute rejection episode. He's taking oral prednisolone and cyclosporine. His lab results show a high C-reactive protein, which suggests an inflammatory response, but his eGFR is 58, which is just below the normal range of 59 or above, so his kidney function isn't significantly impaired.

The doctor ordered rosuvastatin 20mg once daily. Looking at the drug monography, the usual starting dose is 10-20mg once daily. The maximum dose is 40mg, but that's only for patients not achieving their LDL goal with 20mg. The patient's current medications don't include rosuvastatin, so starting at 20mg is appropriate.

I should check for drug interactions. The monography mentions that rosuvastatin should not be used with gemfibrozil, but the patient isn't on that. It also warns about concurrent use with cyclosporine. Oh, the patient is on cyclosporine. The monography says that the dose of rosuvastatin should not exceed 5mg once daily when used with cyclosporine. Wait, the doctor ordered 20mg, which is way higher than the maximum allowed with cyclosporine. That's a problem.

So, the combination of cyclosporine and rosuvastatin could lead to increased toxicity because both are metabolized by the same enzyme, CYP3A4/5. This would increase cyclosporine levels, causing more side effects like nephrotoxicity, which is a concern given the patient's kidney transplant and mild acute rejection.

Therefore, the medication order isn't safe as it violates the drug interaction guidelines. The doctor can only order up to a maximum allowable dose of 5mg since patient is also on Cyclosporine. 

So, the order isn't safe, and the doctor needs to adjust the dosage based on the drug interactions.","The medication order for rosuvastatin 20 mg once daily is not safe for the patient due to a significant drug interaction with cyclosporine. From the drug monography, for patients who are also concomitantly on Cyclosporine, rosuvastatin dose should not exceed 5 mg once daily."
"Patient is a 61 years old male, height 1.62m and weighs 74kg. Latest heart rate is 99 bpm. Latest systolic blood pressure is 142. Patient has past medical history of Hypertension, Hyperlipidemia. Currently patient is admitted for Stroke, Meningitis. 
Patient is also taking the following medications: null. 
Patient has known allergy to: G6PD.

Some recent lab results and reports are shown below:
White Blood Cell = 10.1 10^9/L
Haemoglobin = 10.5 g/dL
Platelet = 125.0 g/dL
Creatinine Clearance = 65.0 mL/min
eGFR = 56.0 mL/min/1.73 mÂ²
Sodium = 146 mmol/L
Potassium = 3.9 mmol/L
Magnesium = 0.85 mmol/L
Fasting Glucose = 7.6 mmol/L
HbA1C = 6.9 %
Hdl Hdl = 1.2 mmol/L
LDL = 3.8 mmol/L
TG = 1.6 mmol/L
Microbiology Report: null
Imaging Report: CT Brain: The findings are consistent with a hemorrhagic stroke. Acute left frontal lobe intraparenchymal hemorrhage with surrounding edema and mild mass effect. Mild midline shift without evidence of herniation. No evidence of subarachnoid hemorrhage or significant ischemic changes outside the hemorrhagic region.

The doctor ordered oral rosuvastatin 10mg every night.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION Rosuvastatin tablets can be taken with or without food, at any time of day. (2.1) Dose range: 5 to 40 mg once daily. Use 40 mg dose only for patients not reaching LDLâ€‘C goal with 20 mg. (2.1) Adult HoFH: Starting dose 20 mg/day (2.1) 2.1 General Dosing Information The dose range for rosuvastatin tablet in adults is 5 to 40 mg orally once daily. The usual starting dose is 10 to 20 mg once daily. The usual starting dose in adult patients with homozygous familial hypercholesterolemia is 20 mg once daily. The maximum rosuvastatin tablet dose of 40 mg should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose [ see Warnings and Precautions (5.1) ]. Rosuvastatin tablets can be administered as a single dose at any time of day, with or without food. The tablet should be swallowed whole. When initiating rosuvastatin therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate rosuvastatin tablets starting dose should first be utilized, and only then titrated according to the patientâ€™s response and individualized goal of therapy. After initiation or upon titration of rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. Pediatric use information for patients 7 to 17 years of age is approved for AstraZenecaâ€™s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZenecaâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 2.3 Dosing in Asian Patients In Asian patients, consider initiation of rosuvastatin therapy with 5 mg once daily due to increased rosuvastatin plasma concentrations. The increased systemic exposure should be taken into consideration when treating Asian patients not adequately controlled at doses up to 20 mg/day [ see Use in Specific Populations (8.8) and Clinical Pharmacology (12.3) ]. 2.4 Use with Concomitant Therapy Patients taking cyclosporine and darolutamide The dose of rosuvastatin tablets should not exceed 5 mg once daily [ see Warnings and Precautions (5.1) , Drug Interactions (7.1) , Drug Interactions (7.4) and Clinical Pharmacology (12.3) ]. Patients taking gemfibrozil Avoid concomitant use of rosuvastatin with gemfibrozil. If concomitant use cannot be avoided, initiate rosuvastatin tablets at 5 mg once daily. The dose of rosuvastatin tablets should not exceed 10 mg once daily [ see Warnings and Precautions (5.1), Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. Patients taking regorafenib Concomitant use of rosuvastatin tablets and regorafenib, the dose of rosuvastatin tablets should not exceed 10 mg once daily [ see Warnings and Precautions (5.1), Drug Interactions (7.5) and Clinical Pharmacology (12.3) ]. Patients taking atazanavir and ritonavir, lopinavir and ritonavir, simeprevir or combination of dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir Initiate rosuvastatin therapy with 5 mg once daily. The dose of rosuvastatin tablets should not exceed 10 mg once daily [ see Warnings and Precautions (5.1) , Drug Interactions (7.3), and Clinical Pharmacology (12.3) ]. 2.5 Dosing in Patients with Severe Renal Impairment For patients with severe renal impairment (CL cr <30 mL/min/1.73 m 2 ) not on hemodialysis, dosing of rosuvastatin tablets should be started at 5 mg once daily and not exceed 10 mg once daily [ see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]. 8.1 Pregnancy Risk Summary Rosuvastatin is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit to therapy with rosuvastatin during pregnancy. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, rosuvastatin may cause fetal harm when administered to pregnant women. Rosuvastatin should be discontinued as soon as pregnancy is recognized [see Contraindications (4) ] . Limited published data on the use of rosuvastatin are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage. In animal reproduction studies, there were no adverse developmental effects with oral administration of rosuvastatin during organogenesis at systemic exposures equivalent to a maximum recommended human dose (MRHD) of 40 mg/day in rats or rabbits (based on AUC and body surface area, respectively). In rats and rabbits, decreased pup/fetal survival occurred at 12 times and equivalent, respectively, to the MRHD of 40 mg/day [see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Limited published data on rosuvastatin have not shown an increased risk of major congenital malformations or miscarriage. Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. The number of cases is adequate to exclude a â‰¥3 to 4-fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Animal Data Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. A higher fetal tissue distribution (25% maternal plasma concentration) was observed in rabbits after a single oral gavage dose of 1 mg/kg on gestation day 18. Rosuvastatin administration did not indicate a teratogenic effect in rats at â‰¤25 mg/kg/day or in rabbits â‰¤3 mg/kg/day (doses equivalent to the MRHD of 40 mg/day based on AUC and body surface area, respectively). In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC). In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area). In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).","Okay, so I need to determine if the doctor's order for rosuvastatin is safe for this patient. Let's break down the information given.

First, the patient is a 61-year-old male with a history of hypertension and hyperlipidemia. He's currently admitted for stroke and meningitis. His current medications are listed as null, which is a bit odd, but maybe he's on other meds not listed here. He has a known allergy to G6PD, which is important to note for future reference.

Looking at his lab results:
- White Blood Cell: 10.1 x10^9/L, which is within normal range.
- Hemoglobin: 10.5 g/dL, slightly low but not critically so.
- Platelet: 125.0 g/dL, within normal range.
- Creatinine Clearance: 65.0 mL/min, which is slightly below normal but still within the normal range for eGFR.
- eGFR: 56.0 mL/min/1.73 mÂ², which is mildly reduced. This might be a concern for possible drug excretion or dosage adjustment.
- Sodium: 146 mmol/L, slightly low but within the normal range.
- Potassium: 3.9 mmol/L, within normal.
- Magnesium: 0.85 mmol/L, which is normal.
- Fasting Glucose: 7.6 mmol/L, slightly elevated but not diabetic.
- HbA1C: 6.9%, which is slightly high, indicating possible prediabetes or diabetes control issues.
- Lipid levels: HDL 1.2 mmol/L (low), LDL 3.8 mmol/L, and TG 1.6 mmol/L. His LDL is high, which is why he's on rosuvastatin.

Microbiology and imaging reports show he has a hemorrhagic stroke with significant findings, which might impact his ability to metabolize certain medications or recover.

The doctor ordered oral rosuvastatin 10mg every night. Looking at the drug monography:

- It can be taken with or without food.
- The dose range is 5 to 40 mg once daily. The usual starting dose is 10-20 mg.
- For patients not on 20 mg and not achieving LDL goals, 40 mg can be used.
- In Asian patients, start at 5 mg due to increased plasma concentration.
- Contraindications include pregnancy, which isn't an issue here.
- Interactions: It mentions cyclosporine, darolutamide, gemfibrozil, regorafenib, and others. The patient isn't on these, so that's good.
- Dose adjustment in renal impairment: His creatinine clearance is 65, which is good, means no sign of renal impairment. If it were <30, he'd need a lower dose.

The patient's current labs don't show any immediate contraindications to rosuvastatin. However, his eGFR is slightly reduced, which might affect drug excretion. At 56 mL/min, it's not severely impaired, so rosuvastatin can still be used.

His HbA1c is slightly high, which could be due to stress or other factors, but not directly related to rosuvastatin.
His current creatinine is 65, which is not too high, and eGFR is 56, which is not severely impaired. The medication seems okay.
In conclusion, the order seems safe given his labs, but close monitoring of renal function and muscle symptoms is necessary.","The medication order is safe because it aligns with the drug monograph and contains no conflicting information. The patient does not have renal impairment. And patient is not on any interacting concomitant drugs. Close monitoring of renal function and muscle symptoms is recommended, as is ensuring the patient's other medical conditions are stabilized."
"Patient is a 63 years old male, height 1.72m and weighs 90kg. Latest heart rate is 80 bpm. Latest systolic blood pressure is 122. Patient has past medical history of Chronic Kidney Disease. Currently patient is admitted for Right Lower Limb Cellulitis . 
Patient is also taking the following medications: Subcutaneous Epoetin Beta Prefilled Syringe 4000u 3 times per week, Oral Renal Vitamin 1 tab every night. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 13.6 10^9/L
Haemoglobin = 11.3 g/dL
Platelet = 355.0 g/dL
High Sensitive C-Reactive Protein = 271.8 mg/L
Urea = 5.4 mmol/L
Creatinine Clearance = 15.0 mL/min
eGFR = 10.0 mL/min/1.73 mÂ²
Sodium = 141 mmol/L
Potassium = 3.8 mmol/L
Magnesium = 0.7 mmol/L
Bicarbonate = 24.0 mmol/L
AST = 42.0 U/L
ALT = 34.0 U/L
Microbiology Report: Investigation name is Wound culture, aerobic and anaerobic and Investigation item is Wound Culture (Aerobic and Anaerobic) (NUHS). Abnormal Results: (Heavy) Staphylococcus aureus. Methylcillin sensitive staph aureis. Culture sensitivity results pending
Imaging Report: null

The doctor ordered intravenous cefazolin 2g every 8 hours.","Alright, I'm trying to figure out if the doctor's order of intravenous cefazolin 2g every 8 hours is safe for this patient. Let me start by going through all the information provided.

The patient is a 63-year-old man with Chronic Kidney Disease (CKD) and is currently admitted for Right Lower Limb Cellulitis. He's taking Epoetin Beta and a renal vitamin, which suggests he's managing his CKD with these medications.

Looking at his lab results: White Blood Cell count is 13.6, which is slightly elevated, and his C-reactive protein is 271.8 mg/L, indicating an infection. His kidney function is poor with eGFR 10.0 mL/min/1.73 mÂ² and creatinine clearance of 15.0 mL/min. That means his kidneys are not working well, so drug elimination might be an issue.

The doctor ordered cefazolin, which is a beta-lactam antibiotic. I remember that beta-lactams can be affected by renal function. The monography says that dosage adjustments are needed for patients with reduced renal function. Specifically, for creatinine clearance less than 55 mL/min, they recommend full doses, but with frequency adjustments. For creatinine clearance of 15-34 mL/min, half the usual dose every 12 hours. Since the patient's creatinine clearance is 15.0 mL/min, just above 15, which is in the range that would require half the usual dose every 12 hours.

Wait, the patient's current order is 2g every 8 hours. If we follow the adjusted dose, it should be 1g every 12 hours. So 2g every 8 hours is higher than the adjusted dose, which might lead to toxicity or overexposure, especially with his impaired renal function. Also, the higher dose might not be necessary and could be harmful.

Additionally, the patient has a history of penicillin allergy, but cefazolin is a cephalosporin, which is related. There's a risk of cross-sensitivity, so if he has a reaction, it could be more severe. 

So, putting it all together, the doctor's order is not adjusted for the patient's renal function. The usual dose would be too high, risking toxicity. Therefore, the order is unsafe as it stands. The correct adjustment would be to use half the usual dose every 12 hours. So, the doctor should change the order to 1g every 12 hours instead of 2g every 8 hours.","This order is not safe because this patient because his creatinine clearance 15mL/min. From the drug monography, patients with creatinine clearance rates of 11 to 34 mL/min should be given half the usual dose every 12 hours. Therefore, the recommended dose should be 1g every 12 hours instead of the ordered dose of 2g every 8 hours."
"Patient is a 35 years old female, height 1.48m and weighs 46kg. Latest heart rate is 96 bpm. Latest systolic blood pressure is 120. Patient has past medical history of null. Currently patient is admitted for Facial Cellulitis, Vertigo. 
Patient is also taking the following medications: null. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 15.36 10^9/L
Haemoglobin = 8.1 g/dL
Platelet = 199.0 g/dL
High Sensitive C-Reactive Protein = 109.0 mg/L
Urea = 8.7 mmol/L
Creatinine Clearance = 78.0 mL/min
eGFR = 64.0 mL/min/1.73 mÂ²
Sodium = 141 mmol/L
Potassium = 4.0 mmol/L
Magnesium = 0.8 mmol/L
Microbiology Report: null
Imaging Report: null

The doctor ordered intravenous cefazolin 1g every 8 hours.

Drug Monography Information:
DOSAGE AND ADMINISTRATION Usual Adult Dosage: Type of Infection Dose Frequency Moderate to severe infections 500 mg to 1 gram every 6 to 8 hours Mild infections caused by susceptible gram-positive cocci 250 mg to 500 mg every 8 hours Acute, uncomplicated urinary tract infections 1 gram every 12 hours Pneumococcal pneumonia 500 mg every 12 hours Severe, life-threatening infections (e.g., endocarditis, septicemia)* 1 gram to 1.5 grams every 6 hours * In rare instances, doses of up to 12 grams of Cefazolin for Injection per day have been used. Perioperative Prophylactic Use : To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are: a. 1 gram I.V. or I.M. administered Â½ hour to 1 hour prior to the start of surgery. b. For lengthy operative procedures (e.g., 2 hours or more), 500 mg to 1 gram I.V. or I.M. during surgery (administration modified depending on the duration of the operative procedure). c. 500 mg to 1 gram I.V. or I.M. every 6 to 8 hours for 24 hours postoperatively. It is important that (1) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibiotic levels are present in the serum and tissues at the time of initial surgical incision; and (2) Cefazolin for Injection be administered, if necessary, at appropriate intervals during surgery to provide sufficient levels of the antibiotic at the anticipated moments of greatest exposure to infective organisms. In surgery where the occurrence of infection may be particularly devastating (e.g., openâ€‘heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection may be continued for 3 to 5 days following the completion of surgery. Dosage Adjustment for Patients With Reduced Renal Function: Cefazolin for Injection may be used in patients with reduced renal function with the following dosage adjustments: Patients with a creatinine clearance of 55 mL/min. or greater or a serum creatinine of 1.5 mg % or less can be given full doses. Patients with creatinine clearance rates of 35 to 54 mL/min. or serum creatinine of 1.6 to 3.0 mg % can also be given full doses but dosage should be restricted to at least 8 hour intervals. Patients with creatinine clearance rates of 11 to 34 mL/min. or serum creatinine of 3.1 to 4.5 mg % should be given 1 / 2 the usual dose every 12 hours. Patients with creatinine clearance rates of 10 mL/min. or less or serum creatinine of 4.6 mg % or greater should be given 1 / 2 the usual dose every 18 to 24 hours. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection. Patients undergoing peritoneal dialysis: See CLINICAL PHARMACOLOGY. Pediatric Dosage: In pediatric patients, a total daily dosage of 25 to 50 mg per kg (approximately 10 to 20 mg per pound) of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections. Total daily dosage may be increased to 100 mg per kg (45 mg per pound) of body weight for severe infections. Since safety for use in premature infants and in neonates has not been established, the use of Cefazolin for Injection in these patients is not recommended. Pediatric Dosage Guide Weight 25 mg/kg/day Divided into 3 Doses 25 mg/kg/day Divided into 4 Doses Lbs Kg Approximate Single Dose mg/q 8 h Vol. (mL) needed with dilution of 125 mg/mL Approximate Single Dose mg/q 6 h Vol. (mL) needed with dilution of 125 mg/mL 10 20 30 40 50 4.5 9 13.6 18.1 22.7 40 mg 75 mg 115 mg 150 mg 190 mg 0.35 mL 0.6 mL 0.9 mL 1.2 mL 1.5 mL 30 mg 55 mg 85 mg 115 mg 140 mg 0.25 mL 0.45 mL 0.7 mL 0.9 mL 1.1 mL Weight 50 mg/kg/day Divided into 3 Doses 50 mg/kg/day Divided into 4 Doses Lbs Kg Approximate Single Dose mg/q 8 h Vol. (mL) needed with dilution of 225 mg/mL Approximate Single Dose mg/q 6 h Vol. (mL) needed with dilution of 225 mg/mL 10 20 30 40 50 4.5 9 13.6 18.1 22.7 75 mg 150 mg 225 mg 300 mg 375 mg 0.35 mL 0.7 mL 1 mL 1.35 mL 1.7 mL 55 mg 110 mg 170 mg 225 mg 285 mg 0.25 mL 0.5 mL 0.75 mL 1 mL 1.25 mL In pediatric patients with mild to moderate renal impairment (creatinine clearance of 70 to 40 mL/min.), 60 percent of the normal daily dose given in equally divided doses every 12 hours should be sufficient. In patients with moderate impairment (creatinine clearance of 40 to 20 mL/min.), 25 percent of the normal daily dose given in equally divided doses every 12 hours should be adequate. Pediatric patients with severe renal impairment (creatinine clearance of 20 to 5 mL/min.) may be given 10 percent of the normal daily dose every 24 hours. All dosage recommendations apply after an initial loading dose. RECONSTITUTION Preparation of Parenteral Solution: Parenteral drug products should be SHAKEN WELL when reconstituted, and inspected visually for particulate matter prior to administration. If particulate matter is evident in reconstituted fluids, the drug solutions should be discarded. When reconstituted or diluted according to the instructions below, Cefazolin for Injection is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5Â°C or 41Â°F). Reconstituted solutions may range in color from pale yellow to yellow without a change in potency. Single-Dose Vials: For I.M. injection, I.V. direct (bolus) injection or I.V. infusion, reconstitute with Sterile Water for Injection according to the following table. SHAKE WELL. Discard unused portion. Vial Size Amount of Diluent Approximate Concentration Approximate Available Volume 500 mg 2 mL 225 mg/mL 2.2 mL 1 gram 2.5 mL 330 mg/mL 3 mL Administration Intramuscular Administration: Reconstitute vials with Sterile Water for Injection according to the dilution table above. Shake well until dissolved. Cefazolin for Injection should be injected into a large muscle mass. Pain on injection is infrequent with Cefazolin for Injection. Intravenous Administration: Direct (bolus) injection: Following reconstitution according to the above table, further dilute vials with approximately 5 mL Sterile Water for Injection. Inject the solution slowly over 3 to 5 minutes, directly or through tubing for patients receiving parenteral fluids (see list below). Intermittent or continuous infusion: Dilute reconstituted Cefazolin for Injection in 50 to 100 mL of one of the following solutions: Sodium Chloride Injection, USP 5% or 10% Dextrose Injection, USP 5% Dextrose in Lactated Ringerâ€™s Injection, USP 5% Dextrose and 0.9% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP 5% Dextrose and 0.2% Sodium Chloride Injection, USP Lactated Ringerâ€™s Injection, USP Invert Sugar 5% or 10% in Sterile Water for Injection Ringerâ€™s Injection, USP 5% Sodium Bicarbonate Injection, USP Pregnancy Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice, and rabbits at doses up to 25 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Cefazolin for Injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. WARNINGS BEFORE THERAPY WITH CEFAZOLIN FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFAZOLIN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS GIVEN TO PENICILLINâ€‘SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSSâ€‘HYPERSENSITIVITY AMONG BETAâ€‘LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFAZOLIN FOR INJECTION OCCURS, DISCONTINUE TREATMENT WITH THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefazolin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of â€œantibioticâ€‘associated colitis.â€ After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an oral antibacterial drug clinically effective against C. difficile colitis.","Alright, I'm trying to figure out if the medication order for cefazolin is safe for this patient. Let me go through the information step by step.

First, the patient is a 35-year-old woman with a height of 1.48 meters and a weight of 46 kg. Her latest vital signs are a heart rate of 96 bpm and a systolic blood pressure of 120 mmHg. She doesn't have any past medical history, and she's currently admitted for facial cellulitis and vertigo. She's not taking any medications and has no known allergies.

Looking at her lab results: her white blood cell count is 15.36 x10^9/L, which is elevated, suggesting an infection. Her hemoglobin is 8.1 g/dL, which is within normal range. Platelets are 199.0 g/dL, also normal. High-sensitive C-reactive protein is 109.0 mg/L, which is high, indicating inflammation. Urea is 8.7 mmol/L, and creatinine clearance is 78.0 mL/min, which is within normal range. Her electrolytes (sodium, potassium, magnesium) are also normal.

The doctor ordered intravenous cefazolin 1g every 8 hours. Cefazolin is a cephalosporin, which is a beta-lactam antibiotic. It's used to treat infections caused by gram-positive and some gram-negative bacteria.

Looking at the drug monography, the usual adult dosage for moderate to severe infections is 500 mg to 1 gram every 6 to 8 hours. Since the patient's infection is moderate to severe (based on her elevated WBC and CRP), 1 gram every 8 hours seems appropriate.

Regarding renal function, her creatinine clearance is 78 mL/min, which is above 55 mL/min. The monography states that patients with creatinine clearance of 55 or higher can receive full doses. Therefore, the dosage adjustment isn't needed here.

She doesn't have any allergies to penicillins or cephalosporins, as noted. There's no history of hypersensitivity reactions. The warnings mention pseudomembranous colitis, but since she doesn't have diarrhea, this isn't a concern right now.

In summary, the medication order is safe because the dosage is appropriate for her condition, her renal function is normal, and she has no allergies or contraindications.","The medication order for cefazolin is safe for the patient. The dosage of 1 gram every 8 hours is appropriate for a moderate to severe infection, and her renal function (creatinine clearance of 78 mL/min) does not require dosage adjustment. She has no allergies or contraindications. Therefore, the order is safe."
"Patient is a 43 years old male, height 1.65m and weighs 85kg. Latest heart rate is 78 bpm. Latest systolic blood pressure is 125. Patient has past medical history of Diabetes Melitus Type 2, Hyperlipidemia. Currently patient is admitted for Acute Kidney Injury secondary to Gastroenteritis, Community Acquired Pneumonia. 
Patient is also taking the following medications: null. 
Patient has known allergy to: glipizide.

Some recent lab results and reports are shown below:
White Blood Cell = 9.5 10^9/L
Haemoglobin = 14.7 g/dL
Platelet = 403.0 g/dL
High Sensitive C-Reactive Protein = 21.6 mg/L
Urea = 4.8 mmol/L
Creatinine Clearance = 16.0 mL/min
eGFR = 25.0 mL/min/1.73 mÂ²
Sodium = 137 mmol/L
Potassium = 4.7 mmol/L
AST = 32.0 U/L
ALT = 62.0 U/L
Albumin = 35.0 g/L
Fasting Glucose = 7.8 mmol/L
HbA1C = 7.9 %
Microbiology Report: null
Imaging Report: Chest X-ray: Left lower zone airspace changes and possible small left pleural effusion. Mild right infrahilar airspace changes Biapical pleural thickening/scarring and fibronodular scarring in the right upper zone. The heart size is not accurately assessed on this projection.  Degenerative changes are noted in the imaged spine.

The doctor ordered intravenous ceftriaxone 2g every 12 hours.

Drug Monography Information:
DOSAGE AND ADMINISTRATION Ceftriaxone may be administered intravenously or intramuscularly. However, the intent of this Pharmacy Bulk Package is for the preparation of solutions for intravenous infusion only. Ceftriaxone should be administered intravenously by infusion over a period of 30 minutes. Do not use diluents containing calcium, such as Ringer â€™ s solution or Hartmann â€™ s solution, to reconstitute Ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see WARNINGS ). There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral). NEONATES: Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone. Ceftriaxone is contraindicated in premature neonates (see CONTRAINDICATIONS ). Ceftriaxone is contraindicated in neonates (â‰¤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CONTRAINDICATIONS ). Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy. PEDIATRIC PATIENTS: For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams. For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams. In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days. ADULTS: The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams. If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism. For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended. Generally, Ceftriaxone therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required. When treating infections caused by Streptococcus pyogenes , therapy should be continued for at least 10 days. No dosage adjustment is necessary for patients with impairment of renal or hepatic function (see PRECAUTIONS ). The dosages recommended for adults require no modification in elderly patients, up to 2 gm per day, provided there is no severe renal and hepatic impairment (see PRECAUTIONS ). Pregnancy Teratogenic Effects Pregnancy Category B Reproductive studies have been performed in mice and rats at doses up to 20 times the usual human dose and have no evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity or teratogenicity was demonstrated at a dose approximately 3 times the human dose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nonteratogenic Effects In rats, in the Segment I (fertility and general reproduction) and Segment III (perinatal and postnatal) studies with intravenously administered ceftriaxone, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring, at doses of 586 mg/kg/day or less. WARNINGS Hypersensitivity Reactions Before therapy with Ceftriaxone is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agents or other drugs. This product should be given cautiously to penicillin and other beta-lactam agent-sensitive patients. Antibacterial drugs should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. Serious acute hypersensitivity reactions may require the use of subcutaneous epinephrine and other emergency measures. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions (i.e., anaphylaxis) have been reported. In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Interaction with Calcium-Containing Products Do not use diluents containing calcium, such as Ringerâ€™s solution or Hartmannâ€™s solution, to reconstitute Ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION ). Clostridium difficile - Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ceftriaxone, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Hemolytic Anemia An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone. Severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children. If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the etiology is determined.","Okay, so I'm trying to figure out if the medication order for ceftriaxone is safe for this patient. Let's start by going through the information step by step.

First, the patient is a 43-year-old male with a height of 1.65 meters and a weight of 85 kg. His latest vital signs are a heart rate of 78 bpm and a systolic blood pressure of 125 mmHg. He has a history of Type 2 Diabetes Mellitus and Hyperlipidemia. He's currently admitted for Acute Kidney Injury (AKI) secondary to Gastroenteritis and Community Acquired Pneumonia. 

Looking at his medications, it says he's taking nothing, which is a bit unusual for someone with chronic illness like diabetes and high cholesterol. But maybe he is on diet control. Okay, he has a known allergy to glipizide, which is a diabetes medication, so that's something to note for future treatment options.

Now, the lab results: White blood cell count is 9.5 x10^9/L, which is slightly elevated, maybe indicating an infection. Hemoglobin is 14.7 g/dL, platelets are 403 g/dL which is within normal range. High-sensitive C-reactive protein is 21.6 mg/L, high, suggesting an infection. Urea is 4.8 mmol/L, and creatinine clearance is 16 mL/min, indicating some kidney dysfunction. eGFR is 25 mL/min/1.73mÂ², which is just below normal but not too bad. Sodium and potassium levels are normal. AST is 32 U/L and ALT is 62 U/L, both slightly elevated, possibly from the pneumonia or liver involvement. Albumin is 35 g/L, which is normal. Fasting glucose is 7.8 mmol/L, and HbA1C is 7.9%, which is controlled for diabetes.

Microbiology and imaging reports are null, so no specific info there.

The doctor ordered IV ceftriaxone 2g every 12 hours. I need to check if this is safe.

Looking at the drug monography: It's for intravenous use, usually over 30 minutes. It shouldn't be mixed with calcium-containing solutions. Our patient might be on IV fluids that have calcium, especially in the context of AKI. But there are no IV fluids listed in his concomitant medication. So that is okay. The monography mentions ceftriaxone is safe in adults, with usual doses up to 2 grams a day, not to exceed 4 grams. 4 grams daily is reserved for severe infections, I would assume like meningitis. Although the patient has acute kidney injury with significantly reduced renal function (Creatinine Clearance = 16 mL/min), ceftriaxone generally does not require dosage adjustment solely for renal impairment. However, the prescribed order of 2 grams every 12 hours (totaling 4 grams per day) exceeds the standard recommendation for community-acquired pneumonia, representing an overdose. Therefore, this medication order is not safe due to the excessive dosage relative to the patient's current indication and condition.","This order is not safe because it is an overdose for the indication. The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The patient is having community aquired pneumonia, and the recommended dose is 1g twice a day or 2g once a day. The current ordered dose of 2g twice a day is an overdose and thus it is not safe."
"Patient is a 65 years old male, height 1.8m and weighs 60kg. Latest heart rate is 93 bpm. Latest systolic blood pressure is 117. Patient has past medical history of Parkinson disease, Type 2 Diabetes Mellitus. Currently patient is admitted for Fall, Community Acquired Pneumonia. 
Patient is also taking the following medications: null. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 2.3697 10^9/L
Haemoglobin = 11.4 g/dL
Platelet = 56.0 g/dL
Creatinine Clearance = 65.0 mL/min
eGFR = 56.0 mL/min/1.73 mÂ²
Microbiology Report: null
Imaging Report: Chest X-ray: Right Lower Lobe Pneumonia, Cardiomegaly

The doctor ordered intravenous ceftriaxone 1g every 12 hours.

Drug Monography Information:
DOSAGE AND ADMINISTRATION Ceftriaxone may be administered intravenously or intramuscularly. However, the intent of this Pharmacy Bulk Package is for the preparation of solutions for intravenous infusion only. Ceftriaxone should be administered intravenously by infusion over a period of 30 minutes. Do not use diluents containing calcium, such as Ringer â€™ s solution or Hartmann â€™ s solution, to reconstitute Ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see WARNINGS ). There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral). NEONATES: Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone. Ceftriaxone is contraindicated in premature neonates (see CONTRAINDICATIONS ). Ceftriaxone is contraindicated in neonates (â‰¤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CONTRAINDICATIONS ). Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy. PEDIATRIC PATIENTS: For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams. For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams. In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days. ADULTS: The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams. If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism. For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended. Generally, Ceftriaxone therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required. When treating infections caused by Streptococcus pyogenes , therapy should be continued for at least 10 days. No dosage adjustment is necessary for patients with impairment of renal or hepatic function (see PRECAUTIONS ). The dosages recommended for adults require no modification in elderly patients, up to 2 gm per day, provided there is no severe renal and hepatic impairment (see PRECAUTIONS ). Pregnancy Teratogenic Effects Pregnancy Category B Reproductive studies have been performed in mice and rats at doses up to 20 times the usual human dose and have no evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity or teratogenicity was demonstrated at a dose approximately 3 times the human dose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nonteratogenic Effects In rats, in the Segment I (fertility and general reproduction) and Segment III (perinatal and postnatal) studies with intravenously administered ceftriaxone, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring, at doses of 586 mg/kg/day or less. WARNINGS Hypersensitivity Reactions Before therapy with Ceftriaxone is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agents or other drugs. This product should be given cautiously to penicillin and other beta-lactam agent-sensitive patients. Antibacterial drugs should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. Serious acute hypersensitivity reactions may require the use of subcutaneous epinephrine and other emergency measures. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions (i.e., anaphylaxis) have been reported. In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Interaction with Calcium-Containing Products Do not use diluents containing calcium, such as Ringerâ€™s solution or Hartmannâ€™s solution, to reconstitute Ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION ). Clostridium difficile - Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ceftriaxone, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Hemolytic Anemia An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone. Severe cases of hemolytic anemia, including fatalities, have been reported during treatment in both adults and children. If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the etiology is determined.","Okay, so I'm trying to figure out if the doctor's order for ceftriaxone is safe for this patient. Let me go through the information step by step.

First, the patient is a 65-year-old male with Parkinson's disease and Type 2 Diabetes. He's been admitted for a fall and community-acquired pneumonia. His current medications are listed as null, and he has no known allergies. His lab results show white blood cells at 2.37 billion/L, which is slightly elevated, but not too high. His hemoglobin is 11.4, which is within normal range. Platelets are 56.0, which is also normal. Creatinine clearance is 65 mL/min, and eGFR is 56 mL/min/1.73mÂ², both of which are within normal range. Imaging shows right lower lobe pneumonia and cardiomegaly.

The doctor ordered intravenous ceftriaxone 1g every 12 hours. I need to check if this is safe.

Looking at the drug monography, I see that ceftriaxone can cause hypersensitivity reactions, including anaphylaxis. The patient has no known allergies, but I know that cephalosporins can cause allergic reactions in some people without a history. The lab results show slightly elevated white blood cells, which might be a sign of infection, but it's not significantly high. The patient has pneumonia, so an infection is present.

Another concern is interaction with calcium-containing solutions. The patient's not on calcium, but if there were any IV calcium or parenteral nutrition, that could cause precipitation. However, the patient's not on those, so that's not an issue here.

Looking at the dosing, for adults, the usual dose is 1-2g daily, given once or twice a day. The doctor is giving 1g every 12 hours, which is within the recommended range. The total daily dose would be 2g, which is the upper limit. For a serious infection like pneumonia, especially with cardiomegaly, which might indicate some underlying heart issues, a higher dose might be appropriate, but 1g every 12 hours is still effective.

The patient's age is 65, and the dosing doesn't seem age-specific. The monography says no adjustment is needed for elderly patients without severe renal or hepatic impairment. The eGFR is 56, which is just below the normal of 60, but still within the safe range for ceftriaxone. The renal function isn't significantly impaired, so dosage adjustment isn't needed.

The patient's fall history could be related to his pneumonia or other factors, but that's probably not directly related to the antibiotic. The slight leukocytosis might be reactive to the infection.

I don't see any direct contraindications for using ceftriaxone in this patient. The only absolute contraindications are neonates and premature infants, which don't apply here.

In summary, the doctor's order seems appropriate and safe for this patient.",The medication order is safe because it aligns with the drug monograph and contains no conflicting information.
"Patient is a 58 years old male, height 1.65m and weighs 85kg. Latest heart rate is 89 bpm. Latest systolic blood pressure is 181. Patient has past medical history of Hypertension. Currently patient is admitted for Hypertensive Crisis. 
Patient is also taking the following medications: Oral Bisoprolol 5mg every morning. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
Creatinine Clearance = 24.0 mL/min
eGFR = 26.0 mL/min/1.73 mÂ²
Sodium = 138 mmol/L
Potassium = 4.5 mmol/L
Magnesium = 0.8 mmol/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral enalapril 5mg every morning.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION Hypertension Adult: recommended initial dose is 5 mg once daily. Maximum dose is 40 mg daily (2.1) . Pediatrics: recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily (2.1) . Heart Failure: Initiate at 2.5 mg twice daily. Titrate up to 20 mg twice daily as tolerated (2.2) . Asymptomatic Left Ventricular Dysfunction: Initiate at 2.5 mg twice daily. Titrate up to 10 mg twice daily (2.3) . Enalapril maleate oral solution is a ready-to-use solution intended for oral use only. 2.1 Hypertension Adults : The recommended initial dose in adults is 5 mg taken orally once a day. Titrate upward to maximum of 40 mg daily as needed to help achieve blood pressure goals. The dose may be divided and administered twice daily if the antihypertensive effect diminishes at the end of the dosing interval. Use with diuretics: If additional blood pressure reduction is needed, enalapril maleate oral solution may be administered with a low dose of diuretic. The recommended initial dose in patients taking diuretics is 2.5 mg daily. Dosage Adjustment for Renal Impairment: See table below. The dosage may be titrated upward as needed to a maximum of 40 mg daily. Renal Status Creatinine-Clearance mL/min Initial Dose mg/day Normal or Mild Impairment of Renal Function >30 mL/min 5 mg Moderate to Severe Impairment â‰¤30 mL/min 2.5 mg Dialysis Patients* â€  â€“ 2.5 mg * = [See Warnings and Precautions (5.2) ]. â€  = Should be taken after hemodialysis on dialysis days [see Clinical Pharmacology (12.3) ] . Calculated using ideal body weight. Children greater than 1 month of age: The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. Adjust dose based on blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients [see Clinical Pharmacology (12.3) ] . Enalapril maleate oral solution is not recommended in neonates (i.e., infants 1 month of age or less), preterm infants who have not reached a corrected post-conceptual age of 44 weeks, and in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m 2 . 2.2 Heart Failure The recommended initial dose is 2.5 mg twice a day titrated up to a maximum of 20 mg twice a day, as tolerated. Doses are usually given in combination with diuretics and digitalis. In patients with hyponatremia (serum sodium less than 130 mEq/L) or serum creatinine greater than 1.6 mg/dL, the recommended initial dose is 2.5 mg once daily. Diuretic dose may need to be adjusted to minimize hypovolemia and hypotension. The appearance of hypotension after the initial dose of enalapril maleate oral solution does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. 2.3 Asymptomatic Left Ventricular Dysfunction The recommended initial dose is 2.5 mg twice a day titrated up to a maximum of 10 mg twice a day, as tolerated. Diuretic dose may need to be adjusted [see Dosage and Administration (2.1) ] . WARNING: FETAL TOXICITY When pregnancy is detected, discontinue enalapril maleate oral solution as soon as possible [see Warnings and Precautions (5.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1) . When pregnancy is detected, discontinue enalapril maleate oral solution as soon as possible (5.1) . 8.1 Pregnancy Risk Summary Enalapril maleate oral solution can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue enalapril maleate oral solution as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Adverse reactions in the fetus or in neonates with a history of in utero exposure to enalapril maleate Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, oligohydramnios, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydraminos may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to enalapril maleate oral solution for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occurs in neonates with a history of in utero exposure to enalapril maleate oral solution, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function.","Okay, so I need to determine if the medication order for enalapril 5mg every morning is safe for this patient. Let me go through the information step by step.

First, the patient is a 58-year-old male with a history of hypertension, currently in a hypertensive crisis. His latest systolic blood pressure is 181. He's taking bisoprolol, which is a beta-blocker, so that's good for controlling his blood pressure. He's also 85 kg and 1.65 meters tall.

Looking at the lab results: creatinine clearance is 24 mL/min, and eGFR is 26 mL/min/1.73 m². That's a bit low, patient appears to be having some degree of kidney function impairment. Sodium is 138 mmol/L, which is slightly low but not too bad. Potassium is 4.5, which is within normal range. Magnesium is on the lower end at 0.8 mmol/L; but that is not relevant because enalapril doesn't affect magnesium levels.

The doctor ordered enalapril 5mg daily. From the drug monography, enalapril is an ACE inhibitor. The key warning is about fetal toxicity, but this is not relevant as the patient is a male and cannot possibly be pregnant. The main concern is the safety of enalapril for this patient.

The patient's renal impairment should be a concern here. According to the drug monography information, there is information on Dosage Adjustment for Renal Impairment. Okay, let's look at the information for Renal Status Creatinine-Clearance mL/min. It is stated Moderate to Severe Impairment \u226430 mL/min 2.5 mg. Wait what is \u226430. It could be Unicode character as part of the drug monography source code. Okay let's assume it is Unicode character. The text \u2264 represents the Unicode character ""Less than or equal to"" (≤). This means the drug monograph is saying Moderate to Severe Impairment ≤30 mL/min 2.5 mg. Wait this patient's Creatinine Clearance is 24mL/min which is ≤30 mL/min. The dose recommended is 2.5 mg (I assume they meant daily, since frequency is not provided). The doctor ordered 5 mg every morning, which is higher than the recommended dose for his renal function.

So, the doctor is starting him on a higher dose than what's safe for his kidneys. This could lead to further renal damage such as acute kidney injury or complications.

Therefore, starting enalapril at 5 mg daily without considering the renal impairment is unsafe. The maximum dose allowable for this patient should be 2.5 mg, while monitoring for side effects and kidney function closely.

So, the medication order isn't safe as it's higher than recommended for the patient's renal status.",This order is not safe because the maximum daily dose of Enalapril in patients with Creatinine Clearance ≤ 30 mL/min is 2.5mg daily. This patient's creatinine clearance is 24mL/min. The current ordered dose of 5mg every morning is too high and should be renally dose adjusted to 2.5mg every morning instead. 
"Patient is a 82 years old male, height 1.65m and weighs 62kg. Latest heart rate is 78 bpm. Latest systolic blood pressure is 145. Patient has past medical history of Dysphagia, Nasogastric Tube (NGT), Nonvalvular Atrial Fibrillation, Hypertension, Osteoarthritis. Currently patient is admitted for Aspiration Pneumonia. 
Patient is also taking the following medications: NG Feeding with Ensure Plus three times a day, IV Ceftriaxone 2g 24 hourly, Oral Amlodipine 5mg every morning, Oral Bisoprolol 2.5mg every morning, Oral Aspirin 100mg every morning. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 11.8 10^9/L
Haemoglobin = 10.2 g/dL
Platelet = 240.0 g/dL
High Sensitive C-Reactive Protein = 18.0 mg/L
Urea = 7.8 mmol/L
Creatinine Clearance = 50.0 mL/min
eGFR = 42.0 mL/min/1.73 mÂ²
Sodium = 135 mmol/L
Potassium = 3.8 mmol/L
Creatinine Kinase = 100.0 U/L
Microbiology Report: Sputum Culture: Moderate Growth of Klebsiella pneumoniae
Imaging Report: Chest X-ray: Right Lower Lobe Pneumonia, Cardiomegaly

The doctor ordered oral enalapril 5mg every morning.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION Hypertension Adult: recommended initial dose is 5 mg once daily. Maximum dose is 40 mg daily (2.1) . Pediatrics: recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily (2.1) . Heart Failure: Initiate at 2.5 mg twice daily. Titrate up to 20 mg twice daily as tolerated (2.2) . Asymptomatic Left Ventricular Dysfunction: Initiate at 2.5 mg twice daily. Titrate up to 10 mg twice daily (2.3) . Enalapril maleate oral solution is a ready-to-use solution intended for oral use only. 2.1 Hypertension Adults : The recommended initial dose in adults is 5 mg taken orally once a day. Titrate upward to maximum of 40 mg daily as needed to help achieve blood pressure goals. The dose may be divided and administered twice daily if the antihypertensive effect diminishes at the end of the dosing interval. Use with diuretics: If additional blood pressure reduction is needed, enalapril maleate oral solution may be administered with a low dose of diuretic. The recommended initial dose in patients taking diuretics is 2.5 mg daily. Dosage Adjustment for Renal Impairment: See table below. The dosage may be titrated upward as needed to a maximum of 40 mg daily. Renal Status Creatinine-Clearance mL/min Initial Dose mg/day Normal or Mild Impairment of Renal Function >30 mL/min 5 mg Moderate to Severe Impairment â‰¤30 mL/min 2.5 mg Dialysis Patients* â€  â€“ 2.5 mg * = [See Warnings and Precautions (5.2) ]. â€  = Should be taken after hemodialysis on dialysis days [see Clinical Pharmacology (12.3) ] . Calculated using ideal body weight. Children greater than 1 month of age: The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. Adjust dose based on blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients [see Clinical Pharmacology (12.3) ] . Enalapril maleate oral solution is not recommended in neonates (i.e., infants 1 month of age or less), preterm infants who have not reached a corrected post-conceptual age of 44 weeks, and in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m 2 . 2.2 Heart Failure The recommended initial dose is 2.5 mg twice a day titrated up to a maximum of 20 mg twice a day, as tolerated. Doses are usually given in combination with diuretics and digitalis. In patients with hyponatremia (serum sodium less than 130 mEq/L) or serum creatinine greater than 1.6 mg/dL, the recommended initial dose is 2.5 mg once daily. Diuretic dose may need to be adjusted to minimize hypovolemia and hypotension. The appearance of hypotension after the initial dose of enalapril maleate oral solution does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. 2.3 Asymptomatic Left Ventricular Dysfunction The recommended initial dose is 2.5 mg twice a day titrated up to a maximum of 10 mg twice a day, as tolerated. Diuretic dose may need to be adjusted [see Dosage and Administration (2.1) ] . WARNING: FETAL TOXICITY When pregnancy is detected, discontinue enalapril maleate oral solution as soon as possible [see Warnings and Precautions (5.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1) . When pregnancy is detected, discontinue enalapril maleate oral solution as soon as possible (5.1) . 8.1 Pregnancy Risk Summary Enalapril maleate oral solution can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue enalapril maleate oral solution as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Adverse reactions in the fetus or in neonates with a history of in utero exposure to enalapril maleate Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, oligohydramnios, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydraminos may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to enalapril maleate oral solution for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occurs in neonates with a history of in utero exposure to enalapril maleate oral solution, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function.
","Okay, I need to determine if the medication order for enalapril is safe for this 82-year-old patient. Let me go through the information step by step.

First, the patient's condition: he's in the hospital for aspiration pneumonia. He has a history of dysphagia, which means he might have trouble swallowing, possibly leading to aspiration. He's also got non-valvular atrial fibrillation, hypertension, and osteoarthritis. His current medications include several blood pressure drugs, an antibiotic, and he's on tube feeding.

Looking at his lab results: white blood cells are slightly elevated (11.8), but not extremely high. His hemoglobin is normal, platelets are normal, and hs-CRP is high (18.0), which suggests some inflammation. Urea is a bit high at 7.8, and creatinine clearance is 50 mL/min, which is moderate impairment. His eGFR is 42, so he has some renal dysfunction. Sodium is normal, potassium is slightly low.

The doctor ordered oral enalapril 5mg every morning. From the drug monography, enalapril is an ACE inhibitor used for hypertension and heart failure. It's contraindicated in pregnancy because it can cause fetal harm. The patient is 82, so pregnancy isn't an issue here, but I should check for other contraindications.

He has hypertension, so enalapril is appropriate in that sense. However, considering his renal function, creatinine clearance is 50, which is moderate impairment. The dosing adjustment for renal impairment suggests that for creatinine clearance between 30-50, the dose should be 5 mg once daily. In the monography, it says for adults with normal or mild renal impairment (>30 mL/min), the initial dose is 5 mg once daily. So, the ordered dose is 5 mg, which aligns with the adjusted dose for his renal function.

He doesn't have a history of angioedema or other allergies listed, so that's not a concern. He's on multiple other blood pressure medications (amlodipine, bisoprolol, and aspirin), so adding enalapril should be okay, but the doctor should monitor for hypotension, especially since he's on several agents that can lower blood pressure.

The patient's age is a consideration, but enalapril is commonly used in the elderly for hypertension, as long as there are no other contraindications. His current conditions don't exclude him from using enalapril.

In summary, the enalapril order is safe because it's appropriate for his hypertension, his renal function is moderate, and there are no other contraindications. The dosage adjustment for renal impairment is already accounted for, and the patient isn't pregnant, so the boxed warning doesn't apply here.","The medication order for enalapril is safe for the patient. The enalapril is appropriate for managing his hypertension, and the dosage adjustment for his renal function (creatinine clearance 50 mL/min) is correctly applied (5 mg once daily). There are no other contraindications, to enalapril for this patient. Therefore, the order is safe."
"Patient is a 25 years old female, height 1.55m and weighs 60kg. Latest heart rate is 90 bpm. Latest systolic blood pressure is 134. Patient has past medical history of null. Currently patient is admitted for Dengue in Pregnancy. 
Patient is also taking the following medications: Oral Paracetamol 1g four times a day when necessary for fever pain. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 2.91 10^9/L
Haemoglobin = 13.8 g/dL
Platelet = 142.0 g/dL
Urea = 3.3 mmol/L
Creatinine Clearance = 96.0 mL/min
eGFR = 98.0 mL/min/1.73 mÂ²
Potassium = 134.0 mmol/L
AST = 33.0 U/L
ALT = 6.0 U/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral lisinopril 5mg every morning.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40 mg daily based on blood pressure response. Initiate patients on diuretics at 5 mg once daily ( 2.1 ) Pediatric patients with glomerular filtration rate > 30 mL/min/1.73m 2 : Initial dose in patients 6 years of age and older is 0.07 mg per kg (up to 5 mg total) once daily ( 2.1 ) Heart Failure: Initiate with 5 mg once daily. Increase dose as tolerated to 40 mg daily ( 2.2 ) Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once daily ( 2.3) Renal Impairment: For patients with creatinine clearance > 10 mL/min and < 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the recommended initial dose is 2.5 mg ( 2.4 ) 2.1 Hypertension Initial Therapy in adults: The recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20 mg to 40 mg per day administered in a single daily dose. Doses up to 80 mg have been used but do not appear to give greater effect. Use with Diuretics in Adults If blood pressure is not controlled with lisinopril alone, a low dose of a diuretic may be added (e.g, hydrochlorothiazide, 12.5 mg). After the addition of a diuretic, it may be possible to reduce the dose of lisinopril. The recommended starting dose in adult patients with hypertension taking diuretics is 5 mg once per day. Pediatric Patients 6 Years of Age and Older with Hypertension For pediatric patients with glomerular filtration rate > 30 mL/min/1.73m 2 , the recommended starting dose is 0.07 mg per kg once daily (up to 5 mg total). Dosage should be adjusted according to blood pressure response up to a maximum of 0.61 mg per kg (up to 40 mg) once daily. Doses above 0.61 mg per kg (or in excess of 40 mg) have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY ( 12.3 )] . Lisinopril tablet USP is not recommended in pediatric patients < 6 years or in pediatric patients with glomerular filtration rate < 30 mL/min/1.73m 2 [see USE IN SPECIFIC POPULATIONS ( 8.4 ) and CLINICAL STUDIES ( 14.1 )] . 2.2 Heart Failure The recommended starting dose for lisinopril, when used with diuretics and (usually) digitalis as adjunctive therapy for systolic heart failure, is 5 mg once daily. The recommended starting dose in these patients with hyponatremia (serum sodium < 130 mEq/L) is 2.5 mg once daily. Increase as tolerated to a maximum of 40 mg once daily. Diuretic dose may need to be adjusted to help minimize hypovolemia, which may contribute to hypotension [see WARNINGS AND PRECAUTIONS ( 5.4 ), and DRUG INTERACTIONS ( 7.1 )] . The appearance of hypotension after the initial dose of lisinopril does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. 2.3 Reduction of Mortality in Acute Myocardial Infarction In hemodynamically stable patients within 24 hours of the onset of symptoms of acute myocardial infarction, give lisinopril tablets USP 5 mg orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Dosing should continue for at least six weeks. Initiate therapy with 2.5 mg in patients with a low systolic blood pressure (â‰¤ 120 mmHg and > 100 mm Hg) during the first 3 days after the infarct [see WARNINGS AND PRECAUTIONS ( 5.4 )] . If hypotension occurs (systolic blood pressure â‰¤ 100 mmHg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure < 90 mmHg for more than 1 hour) lisinopril should be withdrawn. 2.4 Dose in Patients with Renal Impairment No dose adjustment of lisinopril is required in patients with creatinine clearance > 30 mL/min. In patients with creatinine clearance â‰¥ 10 mL/min and â‰¤ 30 mL/min, reduce the initial dose of lisinopril to half of the usual recommended dose i.e., hypertension, 5 mg; systolic heart failure, 2.5 mg and acute MI, 2.5 mg. Up titrate as tolerated to a maximum of 40 mg daily. For patients on hemodialysis or creatinine clearance < 10 mL/min, the recommended initial dose is 2.5 mg once daily [see USE IN SPECIFIC POPULATIONS ( 8.7 ) and CLINICAL PHARMACOLOGY ( 12.3 )] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue lisinopril as soon as possible [see WARNINGS AND PRECAUTIONS ( 5.1 )] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see WARNINGS AND PRECAUTIONS ( 5.1 )] . 8.1 Pregnancy Risk Summary Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue lisinopril as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo/Fetal Risk: Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions: Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia and skeletal deformations, including skull hypoplasia, hypotension, and death. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to lisinopril for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occur in neonates with a history of in utero exposure to lisinopril, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function.","Okay, so I need to figure out if the doctor's order for oral lisinopril 5mg every morning is safe for this patient. Let me start by going through the information given.

The patient is a 25-year-old female, 1.55 meters tall, weighing 60 kg. Her heart rate is 90 bpm, and her systolic blood pressure is 134 mmHg. She's admitted for Dengue in Pregnancy. Her past medical history is null, so no previous illnesses. She's currently taking oral Paracetamol for fever and pain, and she doesn't have any allergies listed.

Looking at the lab results: her white blood cell count is slightly low at 2.91 x10^9/L. Her hemoglobin is 13.8 g/dL, which is within normal range. Platelets are 142.0 g/dL, which is also normal. Urea is 3.3 mmol/L, creatinine clearance is 96 mL/min, eGFR is 98 mL/min/1.73 mÂ². Potassium is 134 mmol/L, which is a bit high but still within the normal range. AST is 33 U/L, ALT is 6 U/L, so her liver enzymes are normal.

The micro and imaging reports are null, so no additional info there.

The doctor ordered lisinopril 5mg once daily. Now, looking at the drug monography, I see a significant warning about fetal toxicity. It says that when pregnancy is detected, lisinopril should be discontinued immediately because it can cause injury and death to the fetus. This applies to drugs acting directly on the renin-angiotensin system, which lisinopril does. This medication order is not safe for this patient and needs to be discontinued immediately.

The key points here are:
1. The patient is pregnant, and lisinopril is contraindicated in pregnancy, especially in the second and third trimesters.
2. The doctor's order is for a medication that is unsafe for the fetus.

Therefore, the medication order is unsafe because it poses a significant risk to the developing fetus without a clear medical emergency that justifies this risk.","This order is not safe because Lisinopril is contraindicated in pregnant patients. This patient is pregant. From the drug monograph, lisinopril can cause injury and death to the developing fetus. The doctor should continue ACE inhibitors as soon as possible once pregnancy is detected."
"Patient is a 29 years old female, height 1.56m and weighs 70kg. Latest heart rate is 96 bpm. Latest systolic blood pressure is 136. Patient has past medical history of Hypertension. Currently patient is admitted for Spotting, Pregnancy. 
Patient is also taking the following medications: null. 
Patient has known allergy to: pencillin.

Some recent lab results and reports are shown below:
White Blood Cell = 5.3 10^9/L
Haemoglobin = 11.5 g/dL
Creatinine Clearance = 112.0 mL/min
eGFR = 101.0 mL/min/1.73 mÂ²
Sodium = 136 mmol/L
Potassium = 4.1 mmol/L
Magnesium = 0.9 mmol/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral methyldopa 250mg three times a day.

Drug Monography Information:
DOSAGE & ADMINISTRATION Adults : Initiation of Therapy : The usual starting dosage of methyldopa tablets is 250 mg two to three times a day in the first 48 hours. The daily dosage then may be increased or decreased, preferably at intervals of not less than 2 days, until an adequate response is achieved. To minimize the sedation, start dosage increases in the evening. By adjustment of dosage, morning hypotension may be prevented without sacrificing control of afternoon blood pressure. When methyldopa tablets are given to patients on other antihypertensives, the dose of these agents may need to be adjusted to effect a smooth transition. When methyldopa tablets are given with anti-hypertensives other than thiazides, the initial dosage of methyldopa tablets should be limited to 500 mg daily in divided doses; when methyldopa tablets are added to a thiazide, the dosage of thiazide need not be changed. Maintenance of Therapy : The usual daily dosage of methyldopa tablets is 500 mg to 2 g in two to four doses. Although occasional patients have responded to higher doses, the maximum recommended daily dosage is 3 g. Once an effective dosage range is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. Since methyldopa has a relatively short duration of action, withdrawal is followed by return of hypertension usually within 48 hours. This is not complicated by an overshoot of blood pressure. Occasionally tolerance may occur, usually between the second and third month of therapy. Adding a diuretic or increasing the dosage of methyldopa frequently will restore effective control of blood pressure. A thiazide may be added at any time during methyldopa therapy and is recommended if therapy has not been started with a thiazide or if effective control of blood pressure cannot be maintained on 2 g of methyldopa daily. Methyldopa is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses. Syncope in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses. Pediatric Patients : Initial dosage is based on 10 mg/kg of body weight daily in two to four doses. The daily dosage then is increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3 g daily, whichever is less. (See PRECAUTIONS: Pediatric Use .) Pregnancy Teratogenic Effects . Reproduction studies performed with methyldopa at oral doses up to 1000 mg/kg in mice, 200 mg/kg in rabbits and 100 mg/kg in rats revealed no evidence of harm to the fetus. These doses are 16.6 times, 3.3 times and 1.7 times, respectively, the maximum daily human dose when compared on the basis of body weight; 1.4 times, 1.1 times and 0.2 times, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg. There are, however, no adequate and well-controlled studies in pregnant women in the first trimester of pregnancy. Because animal reproduction studies are not always predictive of human response, methyldopa should be used during pregnancy only if clearly needed. Published reports of the use of methyldopa during all trimesters indicate that if this drug is used during pregnancy the possibility of fetal harm appears remote. In five studies, three of which were controlled, involving 332 pregnant hypertensive women, treatment with methyldopa was associated with an improved fetal outcome. The majority of these women were in the third trimester when methyldopa therapy was begun. In one study, women who had begun methyldopa treatment between weeks 16 and 20 of pregnancy gave birth to infants whose average head circumference was reduced by a small amount (34.2 Â± 1.7 cm vs. 34.6 Â± 1.3 cm [mean Â± 1 S.D.]). Long-term follow-up of 195 (97.5%) of the children born to methyldopa-treated pregnant women (including those who began treatment between weeks 16 and 20) failed to uncover any significant adverse effect on the children. At 4 years of age, the developmental delay commonly seen in children born to hypertensive mothers was less evident in those whose mothers were treated with methyldopa during pregnancy than those whose mothers were untreated. The children of the treated group scored consistently higher than the children of the untreated group on five major indices of intellectual and motor development. At age 7 and one-half, developmental scores and intelligence indices showed no significant differences in children of treated or untreated hypertensive women. WARNINGS It is important to recognize that a positive Coombs test, hemolytic anemia, and liver disorders may occur with methyldopa therapy. The rare occurrences of hemolytic anemia or liver disorders could lead to potentially fatal complications unless properly recognized and managed. Read this section carefully to understand these reactions. With prolonged methyldopa therapy, 10% to 20% of patients develop a positive direct Coombs test which usually occurs between 6 and 12 months of methyldopa therapy. Lowest incidence is at daily dosage of 1 g or less. This on rare occasions may be associated with hemolytic anemia, which could lead to potentially fatal complications. One cannot predict which patients with a positive direct Coombs test may develop hemolytic anemia. Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa. If a positive Coombs test develops during methyldopa therapy, the physician should determine whether hemolytic anemia exists and whether the positive Coombs test may be a problem. For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood. Before treatment is started, it is desirable to do a blood count (hematocrit, hemoglobin, or red cell count) for a baseline or to establish whether there is anemia. Periodic blood counts should be done during therapy to detect hemolytic anemia. It may be useful to do a direct Coombs test before therapy and at 6 and 12 months after the start of therapy. If Coombs-positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued. Usually the anemia remits promptly. If not, corticosteroids may be given and other causes of anemia should be considered. If the hemolytic anemia is related to methyldopa, the drug should not be reinstituted. When methyldopa causes Coombs positivity alone or with hemolytic anemia, the red cell is usually coated with gamma globulin of the lgG (gamma G) class only. The positive Coombs test may not revert to normal until weeks to months after methyldopa is stopped. Should the need for transfusion arise in a patient receiving methyldopa, both a direct and an indirect Coombs test should be performed. In the absence of hemolytic anemia, usually only the direct Coombs test will be positive. A positive direct Coombs test alone will not interfere with typing or cross matching. If the indirect Coombs test is also positive, problems may arise in the major cross match and the assistance of a hematologist or transfusion expert will be needed. Occasionally, fever has occurred within the first 3 weeks of methyldopa therapy, associated in some cases with eosinophilia or abnormalities in one or more liver function tests, such as serum alkaline phosphatase, serum transaminases (SGOT, SGPT), bilirubin, and prothrombin time. Jaundice, with or without fever, may occur with onset usually within the first 2 to 3 months of therapy. In some patients the findings are consistent with those of cholestasis. In others the findings are consistent with hepatitis and hepatocellular injury. Rarely, fatal hepatic necrosis has been reported after use of methyldopa. These hepatic changes may represent hypersensitivity reactions. Periodic determinations of hepatic function should be done particularly during the first 6 to 12 weeks of therapy or whenever an unexplained fever occurs. If fever, abnormalities in liver function tests, or jaundice appear, stop therapy with methyldopa. If caused by methyldopa, the temperature and abnormalities in liver function characteristically have reverted to normal when the drug was discontinued. Methyldopa should not be reinstituted in such patients. Rarely, a reversible reduction of the white blood cell count with a primary effect on the granulocytes has been seen. The granulocyte count returned promptly to normal on discontinuance of the drug. Rare cases of granulocytopenia have been reported. In each instance, upon stopping the drug, the white cell count returned to normal. Reversible thrombocytopenia has occurred rarely.","Alright, let's tackle this problem step by step. The task is to determine whether the medication order for the patient is safe. The patient is a 29-year-old female with a history of hypertension, currently admitted for spotting and pregnancy. She's taking no medications and has a known allergy to penicillin. Her lab results are within normal ranges except for a slightly elevated white blood cell count. The doctor has ordered oral methyldopa 250mg three times a day.

First, I'll review the drug monography provided. Methyldopa is an antihypertensive agent, typically used for managing hypertension. It's noted that the starting dosage is 250 mg two to three times a day, with the daily dosage gradually increased over the first 48 hours. The maximum daily dosage is up to 3 grams, but the usual maintenance dosage is between 500 mg to 2 grams in two to four doses.

The patient is in the first trimester of pregnancy, which is a critical time for fetal development. Methyldopa is mentioned to have limited data on its use during pregnancy, but in the monography, it's stated that animal reproduction studies show no evidence of harm, and in controlled studies with hypertensive women, methyldopa was associated with improved fetal outcomes. However, there are no adequate studies in the first trimester, which is a concern.

The patient's current blood pressure isn't provided, but given her history of hypertension, controlling her blood pressure is crucial, especially during pregnancy to prevent complications like preeclampsia. Methyldopa is a safe option in pregnancy when used appropriately, but the monography does note that higher doses or prolonged use can lead to side effects like hemolytic anemia or liver issues, which need monitoring.

The patient isn't on any other medications, so there's no drug interaction to worry about. Her lab results are mostly normal, but the white blood cell count is slightly elevated. This could be a concern if it's progressing towards leukocytosis, which can have implications for the mother's health.

Considering all this, the medication order seems appropriate. Methyldopa is a safe choice for managing hypertension in pregnancy, and the dosage ordered falls within the recommended range. However, the lack of data in the first trimester and the need for regular monitoring of blood pressure and side effects are important considerations for the healthcare provider to ensure the patient's safety and the health of the fetus.",The medication order is safe because it aligns with the drug monograph and contains no conflicting information. Methyldopa is considered as a safe option for hypertension treatment in pregnant patients. The ordered dose of 250mg three times a day is appropriate according to the drug monograph as well. 
"Patient is a 76 years old male, height 1.64m and weighs 60kg. Latest heart rate is 85 bpm. Latest systolic blood pressure is 141. Patient has past medical history of Nasogastric tube (NGT), Dysphagia, Benign Prostatic Hyperplasia, Osteoporosis. Currently patient is admitted for Hypoactive Delirium. 
Patient is also taking the following medications: Oral Cholecalciferol 1000 every morning. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 2.32 10^9/L
Haemoglobin = 11.3 g/dL
Platelet = 56.0 g/dL
Creatinine Clearance = 59.0 mL/min
eGFR = 80.0 mL/min/1.73 mÂ²
Microbiology Report: null
Imaging Report: null

The doctor ordered nasogastric risedronate sodium 35mg once weekly.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION One 35 mg delayed-release tablet once-a-week ( 2.1 ) Instruct patients to: Take risedronate sodium delayed-release tablet in the morning immediately following breakfast with at least 4 ounces of plain water ( 2.2 ) Avoid lying down for 30 minutes after taking risedronate sodium delayed-release tablet ( 2.2 ) Take supplemental calcium and vitamin D if dietary intake is inadequate ( 2.3 ) 2.1 Treatment of Postmenopausal Osteoporosis [see Indications and Usage (1.1)] The recommended regimen is: one 35 mg delayed-release tablet orally, taken once-a-week 2.2 Important Administration Instructions Instruct patients to do the following: Take risedronate sodium delayed-release tablets in the morning immediately following breakfast. Risedronate sodium delayed-release tablets should be taken immediately following breakfast and not under fasting conditions because of a higher risk of abdominal pain if taken before breakfast when fasting. Swallow risedronate sodium delayed-release tablets whole while in an upright position and with at least 4 ounces of plain water to facilitate delivery to the stomach. Avoid lying down for 30 minutes after taking the medication [ see Warnings and Precautions ( 5.2 ) ]. Do not chew, cut, or crush risedronate sodium delayed-release tablets. 2.3 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [ see Warnings and Precautions ( 5.3 ) ] and to take calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations at a different time of the day as they interfere with the absorption of risedronate sodium delayed-release tablets. 2.4 Administration Instructions for Missed Doses If the once-weekly dose is missed, instruct patients to take one tablet on the morning after they remember and return to taking one tablet once-a-week, as originally scheduled on their chosen day. Patients should not take two tablets on the same day. 8.1 Pregnancy Risk Summary Available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. Discontinue risedronate sodium when pregnancy is recognized. In animal reproduction studies, daily oral administration of risedronate to pregnant rats during organogenesis decreased neonatal survival and body weight at doses approximately 5 and 26 times, respectively, the highest recommended human daily dose of 30 mg (based on body surface area, mg/m2), the dose indicated for treatment of Paget's disease. A low incidence of cleft palate was observed in fetuses of dams treated at doses approximately equal to the 30 mg human daily dose. Delayed skeletal ossification was observed in fetuses of dams treated at approximately 2.5 to 5 times the 30 mg human daily dose. Periparturient mortality due to maternal hypocalcemia occurred in dams and neonates upon daily oral administration of risedronate to pregnant rats during mating and/or gestation starting at doses equivalent to the 30 mg daily human dose. Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of weeks to years. The amount of bisphosphonate incorporated into adult bone available for release into the systemic circulation is directly related to the dose and duration of bisphosphonate use. Consequently, based on mechanism of action of bisphosphonates, there is a potential risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on this risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal data In animal studies, pregnant rats received risedronate sodium during organogenesis at doses 1 to 26 times the human Paget's disease dose of 30 mg/day (based on body surface area, mg/m 2 ). Survival of neonates was decreased in rats treated during gestation with oral doses approximately 5 times the human dose and body weight was decreased in neonates from dams treated with approximately 26 times the human dose. A low incidence of cleft palate was observed in fetuses from female rats treated with oral doses approximately equal to the human dose. The number of fetuses exhibiting incomplete ossification of sternebrae or skull of dams treated with approximately 2.5 times the human dose was significantly increased compared to controls. Both incomplete ossification and unossified sternebrae were increased in fetuses of dams treated with oral doses approximately 5 times the human dose. No significant ossification effects were seen infetuses of rabbits treated with oral doses approximately 7 times the human dose (the highest dose tested). However, 1 of 14 litters were aborted and 1 of 14 litters were delivered prematurely. Periparturient mortality due to maternal hypocalcemia occurred in dams and neonates when pregnant rats were treated daily during mating and/or gestation with oral doses equivalent to the human dose or higher.

","Okay, so I need to determine if the medication order for this 76-year-old patient is safe. Let's break down the information provided.

The patient is a 76-year-old male, 1.64m tall and 60kg. His current vital signs are a heart rate of 85 bpm and a systolic blood pressure of 141 mmHg. He's been admitted for hypoactive delirium. Past medical history includes nasogastric tube use, dysphagia, benign prostatic hyperplasia, and osteoporosis. He's currently taking oral cholecalciferol 1000 IU daily. No allergies are listed.

His lab results show:
- White blood cell count: 2.32 x10^9/L
- Hemoglobin: 11.3 g/dL
- Platelets: 56.0 g/dL
- Creatinine clearance: 59.0 mL/min
- eGFR: 80.0 mL/min/1.73 mÂ²

Microbiology and imaging reports are null.

The doctor ordered nasogastric risedronate sodium 35mg once weekly.

Now, looking at the drug monography:
Risedronate is indicated for osteoporosis. It's a bisphosphonate, so it's taken weekly, preferably in the morning after breakfast, with at least 4 ounces of plain water. It should be swallowed whole while upright to prevent stomach issues. But  our patient is on nasogastric tube. This means the medication needs to be pounded or crushed, and dissolved,  to be able to be flushed down the tube. Risedronate does  not seem to be a suitable treatment option for this patient due to the nasogastric tube. 

The patient's current medications don't include any that would interfere with risedronate absorption, like calcium, antacids, or magnesium-based supplements. He's only taking cholecalciferol, which is vitamin D.

His creatinine clearance is 59.0 mL/min, and eGFR is 80.0 mL/min/1.73 mÂ². Both are within normal ranges, so renal function isn't a concern here.

The main safety concern here is ensuring proper administration. The patient is receiving the medication via nasogastric tube, but the monography specifies that it should be taken orally, not via NG tube. If the tube is used, it might affect absorption or increase the risk of gastrointestinal issues.

Additionally, since the patient has dysphagia, there's a risk of choking if the medication isn't administered correctly. The delayed-release tablet should be taken whole, but if it's being placed into an NG tube, it might break apart or cause other complications.

So, putting it all together, the order is not safe due to the patient's history of dysphagia and the use of an NG tube which raises some concerns about proper absorption and potential complications. The healthcare team should ensure that the medication is administered in a way that minimizes these risks, or consider alternatives.","This order is not safe because risedronate sodium delayed-release tablets should be swallowed whole and not meant to be chewed, cut, or crushed. This patient has dysphagia and has a nasogastric tube, this means all his medications need to be crushed and flushed down his nasogastric tube. Thus, risedronate is not suitable for this patient. Alternative treatment options should be considered"
"Patient is a 82 years old male, height 1.65m and weighs 62kg. Latest heart rate is 78 bpm. Latest systolic blood pressure is 145. Patient has past medical history of Dysphagia, Nasogastric Tube (NGT), Nonvalvular Atrial Fibrillation, Hypertension, Osteoarthritis. Currently patient is admitted for Aspiration Pneumonia. 
Patient is also taking the following medications: NG Feeding with Ensure Plus three times a day, IV Ceftriaxone 2g 24 hourly, Oral Amlodipine 5mg every morning, Oral Bisoprolol 2.5mg every morning, Oral Aspirin 100mg every morning. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 11.8 10^9/L
Haemoglobin = 10.2 g/dL
Platelet = 240.0 g/dL
High Sensitive C-Reactive Protein = 18.0 mg/L
Urea = 7.8 mmol/L
Creatinine Clearance = 50.0 mL/min
eGFR = 42.0 mL/min/1.73 mÂ²
Sodium = 135 mmol/L
Potassium = 3.8 mmol/L
Creatinine Kinase = 100.0 U/L
Microbiology Report: Sputum Culture: Moderate Growth of Klebsiella pneumoniae
Imaging Report: Chest X-ray: Right Lower Lobe Pneumonia, Cardiomegaly

The doctor ordered nasogastric apixaban 5mg two times a day.

Drug Monography Information:
2 DOSAGE & ADMINISTRATION Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation: The recommended dose is 5 mg orally twice daily. ( 2.1 ) In patients with at least 2 of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. ( 2.1 ) Prophylaxis of DVT following hip or knee replacement surgery: The recommended dose is 2.5 mg orally twice daily. ( 2.1 ) Treatment of DVT and PE: The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily. ( 2.1 ) Reduction in the risk of recurrent DVT and PE following initial therapy: The recommended dose is 2.5 mg taken orally twice daily. ( 2.1 ) 2.1 Recommended Dose Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation The recommended dose of apixaban tablets for most patients is 5 mg taken orally twice daily. The recommended dose of apixaban tablets is 2.5 mg twice daily in patients with at least two of the following characteristics: â€¢ age greater than or equal to 80 years â€¢ body weight less than or equal to 60 kg â€¢ serum creatinine greater than or equal to 1.5 mg/dL Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery The recommended dose of apixaban tablets is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. â€¢ In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days. â€¢ In patients undergoing knee replacement surgery, the recommended duration of treatment is 12 days. Treatment of DVT and PE The recommended dose of apixaban tablets is 10 mg taken orally twice daily for the first 7 days of therapy. After 7 days, the recommended dose is 5 mg taken orally twice daily. Reduction in the Risk of Recurrence of DVT and PE The recommended dose of apixaban tablets is 2.5 mg taken orally twice daily after at least 6 months of treatment for DVT or PE [see Clinical Studies ( 14.3 )]. 2.2 Missed Dose If a dose of apixaban tablets is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose. 2.3 Temporary Interruption for Surgery and Other Interventions Apixaban tablets should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding [see Warnings and Precautions (5.2)] . Apixaban tablets should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping apixaban tablets and prior to the intervention is not generally required. Apixaban tablets should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established. 2.4 Converting from or to apixaban Switching from warfarin to apixaban: Warfarin should be discontinued and apixaban started when the international normalized ratio (INR) is below 2.0. Switching from apixaban to warfarin: apixaban affects INR, so that initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue apixaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of apixaban would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range. Switching from apixaban to anticoagulants other than warfarin (oral or parenteral): Discontinue apixaban and begin taking the new anticoagulant other than warfarin at the usual time of the next dose of apixaban. Switching from anticoagulants other than warfarin (oral or parenteral) to apixaban: Discontinue the anticoagulant other than warfarin and begin taking apixaban at the usual time of the next dose of the anticoagulant other than warfarin. 2.5 Combined P-gp and Strong CYP3A4 Inhibitors For patients receiving apixaban tablets doses of 5 mg or 10 mg twice daily, reduce the dose by 50% when apixaban tablet is coadministered with drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, itraconazole, ritonavir) [see Clinical Pharmacology ( 12.3) ]. In patients already taking 2.5 mg twice daily, avoid coadministration of apixaban tablets with combined P-glycoprotein (P-gp) and strong CYP3A4 inhibitors [see Drug Interactions ( 7.1) ]. 2.6 Administration Options For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg apixaban tablets may be crushed and suspended in water, 5% dextrose in water (D5W), or apple juice, or mixed with applesauce and promptly administered orally [see Clinical Pharmacology ( 12.3) ]. Alternatively, apixaban tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a nasogastric tube [see Clinical Pharmacology ( 12.3 )]. Crushed apixaban tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours. BOXED WARNING WARNING: (A) PREMATURE DISCONTINUATION OF APIXABAN INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF APIXABAN INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including apixaban, increases the risk of thrombotic events. If anticoagulation with apixaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.4), Warnings and Precautions (5.1), and Clinical Studies ( 14.1)] . (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: â€¢ use of indwelling epidural catheters â€¢ concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants â€¢ a history of traumatic or repeated epidural or spinal punctures â€¢ a history of spinal deformity or spinal surgery â€¢ optimal timing between the administration of apixaban and neuraxial procedures is not known [see Warnings and Precautions ( 5.3 )] Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions ( 5.3 )]. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions ( 5.3 )]. WARNING: (A) PREMATURE DISCONTINUATION OF APIXABAN INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning. (A) PREMATURE DISCONTINUATION OF APIXABAN INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including apixaban, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if apixaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy. ( 2.4 , 5.1 , 14.1 ) (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. ( 5.3 ) 8.1 Pregnancy Risk Summary The limited available data on apixaban tablets use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery. In animal reproduction studies, no adverse developmental effects were seen when apixaban was administered to rats (orally), rabbits (intravenously) and mice (orally) during organogenesis at unbound apixaban exposure levels up to 4, 1 and 19 times, respectively, the human exposure based on area under plasma-concentration time curve (AUC) at the Maximum Recommended Human Dose (MRHD) of 5 mg twice daily. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Pregnancy confers an increased risk of thromboembolism that is higher for women with underlying thromboembolic disease and certain high-risk pregnancy conditions. Published data describe that women with a previous history of venous thrombosis are at high risk for recurrence during pregnancy. Fetal/Neonatal adverse reactions Use of anticoagulants, including apixaban, may increase the risk of bleeding in the fetus and neonate. Labor or delivery All patients receiving anticoagulants, including pregnant women, are at risk for bleeding. Apixaban tablets use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches [see Warnings and Precautions ( 5.3 )]. Data Animal Data No developmental toxicities were observed when apixaban was administered during organogenesis to rats (orally), rabbits (intravenously) and mice (orally) at unbound apixaban exposure levels 4, 1, and 19 times, respectively, the human exposures at the MRHD. There was no evidence of fetal bleeding, although conceptus exposure was confirmed in rats and rabbits. Oral administration of apixaban to rat dams from gestation day 6 through lactation day 21 at maternal unbound apixaban exposures ranging from 1.4 to 5 times the human exposures at the MRHD was not associated with reduced maternal mortality or reduced conceptus/neonatal viability, although increased incidences of peri-vaginal bleeding were observed in dams at all doses. There was no evidence of neonatal bleeding.","Alright, I need to determine whether the medication order for apixaban is safe for the patient. Let's go through the information step by step.

First, the patient is an 82-year-old man with a history of several conditions: dysphagia, nonvalvular atrial fibrillation, hypertension, osteoarthritis, and currently admitted for aspiration pneumonia. He's taking several medications, including oral bisoprolol and amlodipine, which are both blood pressure and heart rate controlling agents. He's also on IV ceftriaxone, which is an antibiotic, and NG feeding with Ensure Plus.

Looking at the drug monography for apixaban, I see several important warnings. The first is about premature discontinuation increasing thrombotic events. That's a concern because the patient is already at risk for clotting issues, especially with nonvalvular atrial fibrillation. The second warning is about spinal/epidural hematomas. Our patient is admitted for pneumonia, and is unlikely to be going for any neuraxial procedures. The apixaban is being ordered for anticoagulation, which is necessary for preventing clots, especially given his history of AFib. 

The fact that the patient is 82 years old and has multiple comorbidities increases the risk of adverse effects from any medication. However, the benefit of anticoagulation likely outweighs the bleeding risk associated with Apixaban. The dose of 5mg 2 times a day is also an appropriate anticoagulation dose for stroke prevention in Afib patients. 

Our patient is on nasogastric tube. We need to see if Apixaban can be given through NGT. Yes, the monography mentioned that apixaban tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a nasogastric tube. So that is good for our patient.

In conclusion, the order appears safe for our patient. The dose is within the recommended dosing range for stroke prevention in patients with Atrial fibrillation. The doctor and nurses in the ward needs to watch for bleeding risks, as with all blood thinners, but the benefit of apixaban likely outweighs the risks. It can be administered by NGT which is appropriate for the patient too. ","The medication order is safe because it aligns with the drug monograph and contains no conflicting information. The medication is indicated, dose is appropriate. Although patient has a nasogastric tube,  apixaban tablets can be crushed and suspended in water delivered through a nasogastric tube according to the monograph."
"Patient is a 3 years old male, height 0.85m and weighs 18kg. Latest heart rate is 97 bpm. Latest systolic blood pressure is 114. Patient has past medical history of null. Currently patient is admitted for Viral Fever. 
Patient is also taking the following medications: null. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 2.6 10^9/L
Haemoglobin = 13.0 g/dL
Platelet = 164.0 g/dL
Microbiology Report: null
Imaging Report: null

The doctor ordered oral dextrometorphan 5mL  three times a day.

Drug Monography Information:
Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Directions shake bottle well before use measure only with dosing cup provided do not use dosing cup with other products dose as follows or as directed by a doctor mL = milliliter adults and children 12 years of age and over 10 mL every 12 hours, not to exceed 20 mL in 24 hours children 6 to under 12 years of age 5 mL every 12 hours, not to exceed 10 mL in 24 hours children 4 to under 6 years of age 2.5 mL every 12 hours, not to exceed 5 mL in 24 hours children under 4 years of age do not use Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have chronic cough that lasts as occurs with smoking, asthma or emphysema cough that occurs with too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, cough comes back, or occurs with fever, rash or headache that lasts. These could be signs of a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.","Okay, so I need to determine if the medication order for the 3-year-old patient is safe. Let me start by going through all the information provided step by step.

First, the patient is a 3-year-old male with a height of 0.85 meters and a weight of 18 kg. His latest heart rate is 97 bpm, and his systolic blood pressure is 114 mmHg. He has no past medical history and is currently admitted for Viral Fever. He's not taking any medications and has no known allergies.

The doctor has ordered oral dextrometorphan 5mL three times a day. I need to check the drug monography to see if this is safe for a child of this age.

Looking at the drug monography, I see that it's important to note the contraindications. It says not to use dextrometorphan if the patient is currently taking a monoamine oxidase inhibitor (MAOI) or for two weeks after stopping an MAOI. Our patient is not taking any concomitant medications now so that is fine.

The dosing instructions are specific for different age groups. For children 4 to under 6 years of age 2.5 mL every 12 hours, not to exceed 5 mL in 24 hours, for children under 4 years of age do not use. Wait, our patient is 3 years old. Use of dextromethorphan is not recommended for patients under 4 years. This medication order is not safe for our patient who is a 3-year-old. ","This order is not safe because the drug monography do not recommend the use of dextrometorphan in children under the age of 4 years old. This patient is 3 years old, and thus Dextrometorphan is not suitable for this patient. "
"Patient is a 1 years old male, height 0.85m and weighs 18kg. Latest heart rate is 97 bpm. Latest systolic blood pressure is 114. Patient has past medical history of null. Currently patient is admitted for Viral Fever. 
Patient is also taking the following medications: null. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 3.5 10^9/L
Haemoglobin = 13.9 g/dL
Platelet = 164.0 g/dL
Microbiology Report: null
Imaging Report: null

The doctor ordered oral dimenhydrinate 0.5 tablet three times a day.

Drug Monography Information:
Do not use for children under 2 years of age unless directed by a doctor. Directions to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity adults and children 12 years and over 1 to 2 tablets every 4-6 hours; do not exceed 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years 1/2 to 1 tablet every 6-8 hours; do not exceed 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years 1/2 tablet every 6-8 hours; do not exceed 1&1/2 tablets in 24 hours, or as directed by a doctor Warnings Do not use for children under 2 years of age unless directed by a doctor. Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. When using this product marked drowsiness may occur alcohol, sedatives, and tranquilizers may increase drowsiness use caution when driving a motor vehicle or operating machinery avoid alcoholic beverages If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.","Okay, so I'm trying to figure out if the medication order for this 1-year-old boy is safe. Let me go through the information step by step.

First, the patient is a 1-year-old male, which is under 2 years old. The doctor ordered oral dimenhydrinate, also known as Dramine, 0.5 tablet three times a day. I need to check the drug monography to see if this is appropriate.

Looking at the drug monography, it specifically says not to use dimenhydrinate for children under 2 years of age unless directed by a doctor. Since the patient is exactly 1 year old, which is under 2, this seems to violate that warning. Therefore, the order is unsafe because it's not appropriate for a 1-year-old.","This order is not safe because the drug monography do not recommend the use of dimenhydrinate in children under the age of 2 years old. This patient is 1 year old, and thus Dimenhydrinate is not suitable for this patient. "
"Patient is a 43 years old male, height 1.65m and weighs 85kg. Latest heart rate is 78 bpm. Latest systolic blood pressure is 125. Patient has past medical history of Diabetes Melitus Type 2, Hyperlipidemia. Currently patient is admitted for Acute Kidney Injury secondary to Gastroenteritis, Community Acquired Pneumonia. 
Patient is also taking the following medications: null. 
Patient has known allergy to: glipizide.

Some recent lab results and reports are shown below:
White Blood Cell = 9.5 10^9/L
Haemoglobin = 14.7 g/dL
Platelet = 403.0 g/dL
High Sensitive C-Reactive Protein = 21.6 mg/L
Urea = 4.8 mmol/L
Creatinine Clearance = 16.0 mL/min
eGFR = 25.0 mL/min/1.73 mÂ²
Sodium = 137 mmol/L
Potassium = 4.7 mmol/L
AST = 32.0 U/L
ALT = 62.0 U/L
Albumin = 35.0 g/L
Fasting Glucose = 7.8 mmol/L
HbA1C = 7.9 %
Microbiology Report: null
Imaging Report: Chest X-ray: Left lower zone airspace changes and possible small left pleural effusion. Mild right infrahilar airspace changes Biapical pleural thickening/scarring and fibronodular scarring in the right upper zone. The heart size is not accurately assessed on this projection.  Degenerative changes are noted in the imaged spine.

The doctor ordered oral glipizide 5mg twice a day (pre-meal).

Drug Monography Information:
DOSAGE AND ADMINISTRATION There is no fixed dosage regimen for the management of diabetes mellitus with glipizide or any other hypoglycemic agent. In addition to the usual monitoring of urinary glucose, the patientâ€™s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patientâ€™s response to therapy. Short-term administration of glipizide may be sufficient during periods of transient loss of control in patients usually controlled well on diet. In general, glipizide should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia. Initial Dose The recommended starting dose is 5 mg, given before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Titration Dosage adjustments should ordinarily be in increments of 2.5 to 5 mg, as determined by blood glucose response. At least several days should elapse between titration steps. If response to a single dose is not satisfactory, dividing that dose may prove effective. The maximum recommended once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided and given before meals of adequate caloric content. The maximum recommended total daily dose is 40 mg. Maintenance Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided. Total daily doses above 30 mg have been safely given on a b.i.d. basis to long-term patients. In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions (see PRECAUTIONS ). Patients Receiving Insulin As with other sulfonylurea-class hypoglycemics, many stable non-insulin-dependent diabetic patients receiving insulin may be safely placed on glipizide. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages. Several days should elapse between glipizide titration steps. For patients whose daily insulin requirement is greater than 20 units, the insulin dose should be reduced by 50% and glipizide therapy may begin at usual dosages. Subsequent reductions in insulin dosage should depend on individual patient response. Several days should elapse between glipizide titration steps. During the insulin withdrawal period, the patient should test urine samples for sugar and ketone bodies at least three times daily. Patients should be instructed to contact the prescriber immediately if these tests are abnormal. In some cases, especially when patient has been receiving greater than 40 units of insulin daily, it may be advisable to consider hospitalization during the transition period. Patients Receiving Other Oral Hypoglycemic Agents As with other sulfonylurea-class hypoglycemics, no transition period is necessary when transferring patients to glipizide. Patients should be observed carefully (1 to 2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g., chlorpropamide) to glipizide due to potential overlapping of drug effect. When colesevelam is co-administered with glipizide ER, maximum plasma concentration and total exposure to glipizide is reduced. Therefore, glipizide tablets should be administered at least 4 hours prior to colesevelam. Pregnancy Glipizide was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5 to 50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of glipizide. In studies in rats and rabbits, no teratogenic effects were found. There are no adequate and well controlled studies in pregnant women. Glipizide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. Nonteratogenic Effects Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. If glipizide is used during pregnancy, it should be discontinued at least one month before the expected delivery date. WARNINGS SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups ( Diabetes , 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2Â½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of glipizide and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.","Okay, so I need to determine whether the medication order for glipizide is safe for the patient. Let me start by reviewing the information provided.

The patient is a 43-year-old male with a history of type 2 diabetes, hyperlipidemia, and acute kidney injury secondary to gastroenteritis and community-acquired pneumonia. He's currently taking no medications, but his doctor has ordered oral glipizide 5 mg twice daily before meals.

He has a known allergy to glipizide. This is a red flag. Perhaps the patient was previously on glipizide and had a reaction, but the doctor is trying again, which could be risky. But sometimes the allergy can be to the specific formulation rather than the class. Still, the potential for an allergic reaction is present.

The medication order for glipizide is not safe for this patient due to his allergy history. The doctor may consider a glipizide challenge first to assess if it is indeed a true allergy. But for now, this order is not safe. ","This order is not safe because the patient is allergic to glipizide. Please consider alternative treatment options, or consider a glipizide challenge."
"Patient is a 55 years old male, height 1.75m and weighs 78kg. Latest heart rate is 85 bpm. Latest systolic blood pressure is 130. Patient has past medical history of Kidney Transplant, Hyperlipidemia, Hypertension. Currently patient is admitted for Mild Acute Rejection Episode. 
Patient is also taking the following medications: Oral Prednisolone 5mg every morning, Oral Cyclosporine 325mg twice a day. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 9.2 10^9/L
Haemoglobin = 12.5 g/dL
Platelet = 210.0 g/dL
High Sensitive C-Reactive Protein = 10.0 mg/L
Urea = 6.5 mmol/L
Creatinine Clearance = 65.0 mL/min
eGFR = 58.0 mL/min/1.73 mÂ²
Sodium = 138 mmol/L
Potassium = 4.5 mmol/L
Magnesium = 0.8 mmol/L
Calcium = 1.1 mmol/L
Bicarbonate = 22.0 mmol/L
AST = 35.0 U/L
ALT = 40.0 U/L
Albumin = 38.0 g/L
Fasting Glucose = 7.5 mmol/L
HbA1C = 8.2 %
Hdl Hdl = 1.0 mmol/L
LDL = 3.2 mmol/L
TG = 1.5 mmol/L
Microbiology Report: null
Imaging Report: Renal Ultrasound: No hydronephrosis, stable allograft

The doctor ordered oral azathioprine 100mg every morning.

Drug Monography Information:
DOSAGE AND ADMINISTRATION Renal Homotransplantation The dose of azathioprine tablets required to prevent rejection and minimize toxicity will vary with individual patients; this necessitates careful management. The initial dose is usually 3 to 5 mg/kg daily, beginning at the time of transplant. Azathioprine tablets are usually given as a single daily dose on the day of, and in a minority of cases 1 to 3 days before, transplantation. Dose reduction to maintenance levels of 1 to 3 mg/kg daily is usually possible. The dose of azathioprine tablets should not be increased to toxic levels because of threatened rejection. Discontinuation may be necessary for severe hematologic or other toxicity, even if rejection of the homograft may be a consequence of drug withdrawal. Rheumatoid Arthritis Azathioprine tablets are usually given on a daily basis. The initial dose should be approximately 1.0 mg/kg (50 to 100 mg) given as a single dose or on a twice-daily schedule. The dose may be increased, beginning at 6 to 8 weeks and thereafter by steps at 4-week intervals, if there are no serious toxicities and if initial response is unsatisfactory. Dose increments should be 0.5 mg/kg daily, up to a maximum dose of 2.5 mg/kg per day. Therapeutic response occurs after several weeks of treatment, usually 6 to 8; an adequate trial should be a minimum of 12 weeks. Patients not improved after 12 weeks can be considered refractory. Azathioprine tablets may be continued long-term in patients with clinical response, but patients should be monitored carefully, and gradual dosage reduction should be attempted to reduce risk of toxicities. Maintenance therapy should be at the lowest effective dose, and the dose given can be lowered decrementally with changes of 0.5 mg/kg or approximately 25 mg daily every 4 weeks while other therapy is kept constant. The optimum duration of maintenance azathioprine tablets has not been determined. Azathioprine tablets can be discontinued abruptly, but delayed effects are possible. Patients with TPMT and/or NUDT15 Deficiency Consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , and PRECAUTIONS: Laboratory Tests ). Homozygous deficiency in either TPMT or NUDT15 Because of the risk of increased toxicity, consider alternative therapies for patients who are known to have TPMT or NUDT15 deficiency (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , and PRECAUTIONS: Laboratory Tests ). Heterozygous deficiency in TPMT and/or NUDT15 Because of the risk of increased toxicity, dosage reduction is recommended in patients known to have heterozygous deficiency of TPMT or NUDT15. Patients who are heterozygous for both TPMT and NUDT15 deficiency may require more substantial dosage reductions (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , and PRECAUTIONS: Laboratory Tests ). Use in Renal Dysfunction Relatively oliguric patients, especially those with tubular necrosis in the immediate postcadaveric transplant period, may have delayed clearance of azathioprine tablets or its metabolites, may be particularly sensitive to this drug, and are usually given lower doses. Procedures for proper handling and disposal of this immunosuppressive antimetabolite drug should be considered. Several guidelines on this subject have been published. 15-21 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. WARNING - MALIGNANCY Chronic immunosuppression with azathioprine, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with azathioprine. See WARNINGS . Pregnancy Pregnancy Category D. Azathioprine tablets can cause fetal harm when administered to a pregnant woman. Azathioprine tablets should not be given during pregnancy without careful weighing of risk versus benefit. Whenever possible, use of azathioprine tablets in pregnant patients should be avoided. This drug should not be used for treating rheumatoid arthritis in pregnant women. 3 Azathioprine tablets are teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Abnormalities included skeletal malformations and visceral anomalies. 2 Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on azathioprine tablets. In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. At 10 weeks most features were normalized. DeWitte et al reported pancytopenia and severe immune deficiency in a preterm infant whose mother received 125 mg azathioprine and 12.5 mg prednisone daily. 5 There have been two published reports of abnormal physical findings. Williamson and Karp described an infant born with preaxial polydactyly whose mother received azathioprine 200 mg daily and prednisone 20 mg every other day during pregnancy. 6 Tallent et al described an infant with a large myelomeningocele in the upper lumbar region, bilateral dislocated hips, and bilateral talipes equinovarus. The father was on long-term azathioprine therapy. 7 Benefit versus risk must be weighed carefully before use of azathioprine tablets in patients of reproductive potential. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be advised to avoid becoming pregnant. WARNINGS Malignancy Patients receiving immunosuppressants, including azathioprine, are at increased risk of developing lymphoma and other malignancies, particularly of the skin. Physicians should inform patients of the risk of malignancy with azathioprine. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. Post-transplant Renal transplant patients are known to have an increased risk of malignancy, predominantly skin cancer and reticulum cell or lymphomatous tumors. The risk of post-transplant lymphomas may be increased in patients who receive aggressive treatment with immunosuppressive drugs, including azathioprine. Therefore, immunosuppressive drug therapy should be maintained at the lowest effective levels. Rheumatoid Arthritis Information is available on the risk of malignancy with the use of azathioprine in rheumatoid arthritis (see ADVERSE REACTIONS ). It has not been possible to define the precise risk of malignancy due to azathioprine. The data suggest the risk may be elevated in patients with rheumatoid arthritis, though lower than for renal transplant patients. However, acute myelogenous leukemia as well as solid tumors have been reported in patients with rheumatoid arthritis who have received azathioprine. Inflammatory Bowel Disease Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with azathioprine. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Some of the patients were treated with azathioprine as monotherapy and some had received concomitant treatment with a TNFÎ± blocker at or prior to diagnosis. The safety and efficacy of azathioprine for the treatment of Crohn's disease and ulcerative colitis have not been established. Cytopenias Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur in patients being treated with azathioprine. Severe bone marrow suppression may also occur. Hematologic toxicities are dose-related and may be more severe in renal transplant patients whose homograft is undergoing rejection. It is suggested that patients on azathioprine have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary. Delayed hematologic suppression may occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in or persistently low leukocyte count, or other evidence of bone marrow depression. Leukopenia does not correlate with therapeutic effect; therefore the dose should not be increased intentionally to lower the white blood cell count. TPMT or NUDT15 Deficiency Patients with thiopurine S-methyl transferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency may be at an increased risk of severe and life-threatening myelotoxicity if receiving conventional doses of azathioprine (see CLINICAL PHARMACOLOGY ). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine. In patients with severe myelosuppression, consider evaluation for TPMT and NUDT15 deficiency (see PRECAUTIONS: Laboratory Tests ). Consider alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency (see DOSAGE AND ADMINISTRATION ). Serious infections Patients receiving immunosuppressants, including azathioprine, are at increased risk for bacterial, viral, fungal, protozoal, and opportunistic infections, including reactivation of latent infections. These infections may lead to serious, including fatal outcomes. Progressive Multifocal Leukoencephalopathy Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. Consider the diagnosis of PML in any patient presenting with new-onset neurological manifestations and consider consultation with a neurologist as clinically indicated. Consider reducing the amount of immunosuppression in patients who develop PML. In transplant patients, consider the risk that the reduced immunosuppression represents to the graft. Effect on Sperm in Animals Azathioprine has been reported to cause temporary depression in spermatogenesis and reduction in sperm viability and sperm count in mice at doses 10 times the human therapeutic dose; 1 a reduced percentage of fertile matings occurred when animals received 5 mg/kg. 2 Pregnancy Pregnancy Category D. Azathioprine tablets can cause fetal harm when administered to a pregnant woman. Azathioprine tablets should not be given during pregnancy without careful weighing of risk versus benefit. Whenever possible, use of azathioprine tablets in pregnant patients should be avoided. This drug should not be used for treating rheumatoid arthritis in pregnant women. 3 Azathioprine tablets are teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Abnormalities included skeletal malformations and visceral anomalies. 2 Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on azathioprine tablets. In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. At 10 weeks most features were normalized. DeWitte et al reported pancytopenia and severe immune deficiency in a preterm infant whose mother received 125 mg azathioprine and 12.5 mg prednisone daily. 5 There have been two published reports of abnormal physical findings. Williamson and Karp described an infant born with preaxial polydactyly whose mother received azathioprine 200 mg daily and prednisone 20 mg every other day during pregnancy. 6 Tallent et al described an infant with a large myelomeningocele in the upper lumbar region, bilateral dislocated hips, and bilateral talipes equinovarus. The father was on long-term azathioprine therapy. 7 Benefit versus risk must be weighed carefully before use of azathioprine tablets in patients of reproductive potential. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be advised to avoid becoming pregnant.","Given the patient's current clinical scenario and the provided drug monograph, we can assess the medication order systematically. The patient is a 55-year-old male who has undergone kidney transplantation and is experiencing a mild acute rejection episode, an indication that necessitates appropriate immunosuppressive therapy. The drug ordered by the physician is oral azathioprine at a dose of 100mg every morning.

Starting the assessment with patient factors: the patient has a stable allograft confirmed by recent renal ultrasound findings, which report no hydronephrosis or significant structural abnormalities. Laboratory values, including renal function (creatinine clearance at 65.0 mL/min and eGFR at 58.0 mL/min/1.73 m²), suggest moderately reduced kidney function, which is expected in a post-transplant patient and does not contraindicate azathioprine use. The absence of any known allergies further supports safe initiation of the medication.

The drug monograph indicates that azathioprine’s initial dosing in renal transplant patients typically ranges from 3 to 5 mg/kg/day at the time of transplantation, with a maintenance dose subsequently reduced to 1 to 3 mg/kg/day. Considering the patient’s weight (78 kg), the prescribed daily maintenance dose range would thus fall approximately between 78 mg (1 mg/kg/day) and 234 mg (3 mg/kg/day). The physician’s ordered dose of 100 mg per day comfortably falls within this recommended therapeutic range and is thus appropriately conservative, minimizing risks of toxicities while providing sufficient immunosuppression to manage the current mild rejection episode.

Examining the patient's concomitant medications—prednisolone 5 mg daily and cyclosporine 325 mg twice daily—we see a comprehensive regimen typical of renal transplant management. Importantly, azathioprine is commonly utilized as part of multidrug regimens in transplantation medicine, complementing corticosteroids and calcineurin inhibitors such as cyclosporine. There are no reported or apparent pharmacologic contraindications between azathioprine and these medications, based on the provided drug monograph and current clinical practice guidelines.

Additionally, laboratory tests demonstrate normal platelet levels, white blood cell counts within acceptable ranges, and no severe hepatic enzyme abnormalities. These parameters indicate a stable hematological and hepatic profile, reducing the risk of hematologic toxicity, one of the primary safety concerns with azathioprine therapy. Also noteworthy, the patient’s clinical data do not indicate deficiencies or testing results for TPMT or NUDT15 enzymes, which would otherwise necessitate dosage adjustments. Therefore, we can infer the absence of enzyme deficiency unless explicitly stated.

Taking into account all clinical, laboratory, and medication data collectively, the ordered azathioprine dose is appropriate for the patient's clinical scenario. The medication order aligns closely with the recommendations provided in the drug monograph, presents no interactions or contraindications with other therapies, and fits well within established dosing guidelines for renal transplant maintenance therapy.

Thus, the medication order is safe because it aligns with the drug monograph and contains no conflicting information. The patient does not have any allergy status, and no contraindications to azathioprine exist. The ordered dose of 100mg every morning is appropriate as a maintenance dose as well.","The medication order is safe because it aligns with the drug monograph and contains no conflicting information. The patient does not have any allergy status, and no contraindications to azathioprine. Orderd dose of 100mg every morning is appropriate for maintenance dose as well."
"Patient is a 31 years old male, height 1.68m and weighs 86kg. Latest heart rate is 87 bpm. Latest systolic blood pressure is 119. Patient has past medical history of Hypertension. Currently patient is admitted for Rhabdomylosis, Transaminitis. 
Patient is also taking the following medications: Oral Atenolol 50mg two times a day. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 9.56 10^9/L
Haemoglobin = 14.9 g/dL
Platelet = 318.0 g/dL
Urea = 2.8 mmol/L
eGFR = 111.0 mL/min/1.73 mÂ²
Sodium = 138 mmol/L
Potassium = 4.0 mmol/L
Bicarbonate = 28.0 mmol/L
AST = 73.0 U/L
ALT = 160.0 U/L
Albumin = 46.0 g/L
Creatinine Kinase = 52275.0 U/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral amlodipine 5mg every morning.

Drug Monography Information:
2 DOSAGE AND ADMINISTRATION Adult recommended starting dose: 5 mg orally once daily with maximum dose 10 mg once daily. (2.1) Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily. (2.1) Pediatric starting dose: 2.5 mg to 5 mg once daily. (2.2) Important Limitation: Doses in excess of 5 mg daily have not been studied in pediatric patients. (2.2) SHAKE BEFORE USING 2.1 Adults The usual initial antihypertensive oral dose of amlodipine oral suspension is 5 mg orally once daily, and the maximum dose is 10 mg once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine oral suspension to other antihypertensive therapy [see Use in Specific Populations (8.6) ] . Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently. Angina: The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg once daily, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg once daily for adequate effect. Coronary artery disease: The recommended dose range for patients with coronary artery disease is 5 to 10 mg once daily. In clinical studies, the majority of patients required 10 mg once daily [see Clinical Studies (14.4) ] . 2.2 Children The effective antihypertensive oral dose in pediatric patients ages 6 to 17 years is 2.5 to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients [see Clinical Pharmacology (12.3) , Clinical Studies (14.1) ] . 8.1 Pregnancy Risk Summary The limited available data based on post-marketing reports with amlodipine use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when pregnant rats and rabbits were treated orally with amlodipine maleate during organogenesis at doses approximately 10 and 20-times the maximum recommended human dose (MRHD), respectively. However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold). Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose [see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Data Animal Data No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (approximately 10 and 20 times the MRHD based on body surface area, respectively) during their respective periods of major organogenesis. However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.","Alright, I need to determine if the medication order for amlodipine is safe for the patient. Let me go through the information step by step.

First, the patient is a 31-year-old male with a history of hypertension and currently admitted for rhabdomyolysis and transaminitis. His current medications include oral atenolol 50mg twice a day. He has no known allergies.

Looking at the lab results: His eGFR is 111 mL/min/1.73 mÂ², which is within the normal range (usually above 59-60 is considered normal). His creatinine kinase is very high at 52,275 U/L, which is concerning because rhabdomyolysis can cause muscle breakdown and lead to kidney issues. His AST is 73 U/L and ALT is 160 U/L, which are elevated but not as high as in some cases of rhabdomyolysis.

The doctor ordered amlodipine 5mg once daily. From the drug monography, the recommended starting dose for adults is 5mg once daily, so that part is appropriate. However, I need to consider if amlodipine is safe in this patient's condition.

Amlodipine is a calcium channel blocker and is generally well-tolerated, but it can cause side effects like hypotension, dizziness, headache, and swelling. Since the patient has rhabdomyolysis, which can lead to acute kidney injury, I need to check if amlodipine would be contraindicated or if it's safe.

Looking at the drug monography, there's no specific contraindication mentioned for amlodipine in this scenario. However, the patient's condition (rhabdomyolysis) could be a risk factor. Rhabdomyolysis can cause hyperkalemia, which is noted in the lab results (potassium is 4.0 mmol/L, which is within normal range). The eGFR is still normal, so kidney function isn't severely affected yet.

The patient's blood pressure is slightly elevated (systolic 119), and amlodipine is used for hypertension. The current medication is atenolol, another antihypertensive, so adding amlodipine could be appropriate if the blood pressure isn't well-controlled. However, I should check for drug interactions.

Amlodipine and atenolol are both antihypertensives, and there's no known significant interaction between them that would cause harm in this context. Atenolol is a beta-blocker, and amlodipine is a calcium channel blocker; they can be used together without issues, though combined they might have additive effects on blood pressure.

The patient's current condition (rhabdomyolysis) is more concerning. Rhabdomyolysis can lead to acute kidney injury, which is why creatinine kinase is high. The eGFR is still normal, but it's a sign that the kidneys are functioning adequately for now. The main risk is that if the rhabdomyolysis progresses, the eGFR could drop, leading to dialysis or other interventions.

The amlodipine dose is appropriate, but the overall patient safety depends on managing the rhabdomyolysis. Since the doctor is ordering amlodipine for hypertension, it's safe to proceed as long as the patient's blood pressure is monitored and the rhabdomyolysis is treated appropriately.

In summary, based on the drug monography, the amlodipine dose is appropriate. The patient's condition (rhabdomyolysis) doesn't directly contraindicate amlodipine. Therefore, the medication order is safe.","The medication order for amlodipine 5mg once daily is safe for the patient based on the provided information. The amlodipine dose aligns with the recommended adult starting dose, and there are no specific contraindications mentioned in the drug monography that would prevent its use. The patient's condition, rhabdomyolysis, does not directly contraindicate amlodipine but requires careful monitoring of blood pressure and management of the underlying condition. Therefore, the order is appropriate."
"Patient is a 46 years old male, height 1.68m and weighs 86kg. Latest heart rate is 87 bpm. Latest systolic blood pressure is 119. Patient has past medical history of Vertigo. Currently patient is admitted for Newly Diagnosed Type 2 Diabetes Mellitus, Recurrent Cellulitis. 
Patient is also taking the following medications: null. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
Creatinine Clearance = 47.0 mL/min
eGFR = 40.0 mL/min/1.73 mÂ²
Fasting Glucose = 9.1 mmol/L
HbA1C = 8.1 %
Microbiology Report: null
Imaging Report: null

The doctor ordered oral betahistine 24mg every morning.

Error: 404, drug monography not available.","Alright, so I'm trying to figure out if the medication order for this patient is safe. The patient is a 46-year-old male with a history of vertigo, type 2 diabetes, and recurrent cellulitis. He's taking no medications currently and has no allergies. His latest vitals are a heart rate of 87 bpm and systolic blood pressure of 119 mmHg. His labs show a creatinine clearance of 47 mL/min and an eGFR of 40 mL/min/1.73 mÂ², which are slightly below normal but not too concerning. His fasting glucose is 9.1 mmol/L, and HbA1C is 8.1%, indicating he's managing his diabetes, though not perfectly.

The doctor has ordered oral betahistine 24mg every morning. Now, the issue here is that the drug monography for betahistine isn't available, which means I can't access its usual information like dosage, side effects, interactions, or contraindications. Without that, I can't definitively determine if this order is safe.

Betahistine is typically used for vertigo, which the patient has a history of. It's also used sometimes for tinnitus and can have side effects like dizziness, headache, and gastrointestinal issues. However, without knowing the patient's current medications, existing conditions, and potential allergies, it's hard to assess. For instance, if he's on other medications that interact with betahistine, that could be a problem.

Also, considering his diabetes, I need to check if betahistine affects blood sugar levels. If it does, that could complicate his management. Additionally, his eGFR is a bit low, so I'd want to ensure that betahistine isn't causing any kidney issues, though it's generally well-tolerated in most cases.

Since the drug monography isn't available, I can't confirm if this order is safe. Without that information, the order is considered unsafe because there's insufficient data to ensure it won't cause harm. The doctor might need to proceed with caution or consider alternative treatments if betahistine isn't suitable.

In summary, without the necessary information about betahistine, the order can't be deemed safe for the patient. The doctor should either obtain the monography or consider other options to manage the vertigo and diabetes safely.",The medication order is unsafe due to insufficient information. There is no information for the drug monograph. Verification by a pharmacist is required.
"Patient is a 35 years old female, height 1.48m and weighs 46kg. Latest heart rate is 96 bpm. Latest systolic blood pressure is 120. Patient has past medical history of null. Currently patient is admitted for Facial Cellulitis, Vertigo. 
Patient is also taking the following medications: null. 
Patient has known allergy to: null.

Some recent lab results and reports are shown below:
White Blood Cell = 15.36 10^9/L
Haemoglobin = 8.1 g/dL
Platelet = 199.0 g/dL
High Sensitive C-Reactive Protein = 109.0 mg/L
Urea = 8.7 mmol/L
Creatinine Clearance = 78.0 mL/min
eGFR = 64.0 mL/min/1.73 mÂ²
Sodium = 141 mmol/L
Potassium = 4.0 mmol/L
Magnesium = 0.8 mmol/L
Microbiology Report: null
Imaging Report: null

The doctor ordered oral cinnarizine 15mg three times a day.

Error: 404, drug monography not available.","Okay, so I need to determine if the medication order for this patient is safe. Let's start by looking at the information given.

The patient is a 35-year-old female with a height of 1.48m and weight of 46kg. Her latest heart rate is 96 bpm, and her systolic blood pressure is 120 mmHg. She has no past medical history and is currently admitted for facial cellulitis and vertigo. She isn't taking any other medications and has no known allergies.

Looking at her lab results, her white blood cell count is 15.36 x10^9/L, which is slightly elevated. Her hemoglobin is 8.1 g/dL, which is within the normal range. Platelets are 199.0 g/dL, which is normal. Her high-sensitive C-reactive protein is 109.0 mg/L, which is high, suggesting an infection. Urea is 8.7 mmol/L, which is within normal range. Creatinine clearance is 78.0 mL/min, and her eGFR is 64.0 mL/min/1.73 mÂ², both of which are normal. Sodium, potassium, and magnesium levels are also normal.

The doctor ordered oral cinnarizine 15mg three times a day. But the drug monography isn't available, so I can't look up the typical uses, dosing, side effects, or interactions.

Cinnarizine is typically used for vertigo, dizziness, or motion sickness. It's often used in the short-term for acute conditions. However, without knowing the specific brand and formulation, it's hard to assess. Also, since the patient has facial cellulitis, which is an infection, I wonder if cinnarizine could interact with any other medications she might be taking, but since she's not on any other meds, that's less of a concern.

Another point is her elevated C-reactive protein. Facial cellulitis can be bacterial or viral. If it's bacterial, treating with antibiotics might be necessary, but since the monography isn't available, I don't know if cinnarizine would interfere with that.

Also, her weight is 46kg, and the dosage is 15mg three times a day. That's 45mg per day. I don't know if that's within the usual range for adults. If she's underweight, maybe a lower dose is appropriate, but without knowing the indication, it's hard to say.

Since the monography isn't available, I can't confirm if this is a safe order. Without knowing the specific drug's profile, there's a risk of unknown interactions or side effects, especially considering her current condition.

So, in conclusion, without the drug monography, I can't safely determine if the order is appropriate. The order might be unsafe due to insufficient information.",The medication order is unsafe due to insufficient information. There is no information for the drug monograph. Verification by a pharmacist is required.
